WO2015136446A1 - Méthodes de choix de traitement par antidépresseur pour traiter la dépression - Google Patents

Méthodes de choix de traitement par antidépresseur pour traiter la dépression Download PDF

Info

Publication number
WO2015136446A1
WO2015136446A1 PCT/IB2015/051741 IB2015051741W WO2015136446A1 WO 2015136446 A1 WO2015136446 A1 WO 2015136446A1 IB 2015051741 W IB2015051741 W IB 2015051741W WO 2015136446 A1 WO2015136446 A1 WO 2015136446A1
Authority
WO
WIPO (PCT)
Prior art keywords
individual
allele
antidepressant drug
sample
drug
Prior art date
Application number
PCT/IB2015/051741
Other languages
English (en)
Inventor
Sharat Singh
Original Assignee
Nestec S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec S.A. filed Critical Nestec S.A.
Publication of WO2015136446A1 publication Critical patent/WO2015136446A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • Clinical guidelines for treating depression recommend four possible strategies for managing non-response or partial response. These include: increasing the dose of the antidepressant drug; replacing the drug with a different antidepressant drug; augmenting the antidepressent therapy with a non-antidepressant agent; or combining the initial antidepressant with a second antidepressant.
  • increasing the dose of the antidepressant drug replacing the drug with a different antidepressant drug
  • augmenting the antidepressent therapy with a non-antidepressant agent or combining the initial antidepressant with a second antidepressant.
  • the present invention provides a method for selecting a suitable treatment for an individual diagnosed with depression.
  • the method comprises (a) detecting the presence or absence of the following single nucleotide polymorphisms (SNPs) in a sample obtained from the individual: (i) a SNP at position 27 of SEQ ID NO: l comprising at least one thymine "T" allele or the complement thereof for MTHFR (rs 1801 133); (ii) a SNP at position 27 of SEQ ID NO:2 comprising at least one guanine "G" allele or the complement thereof for MTR (rsl 805087); (iii) a SNP at position 27 of SEQ ID NO:3 comprising at least one thymine "T” allele or the complement thereof for GCH1 (rs8007267); and (iv) a SNP at position 27 of SEQ ID NO:4 comprising at least one guanine "G” allele or the complement thereof for COMT (rs46
  • the antidepressant drug comprises a selective serotonin reuptake inhibitor (SSRI).
  • SSRI can be selected from the group consisting of fluoxetine, citalopram, paroxetine, escitalopram, sertraline and a combination thereof.
  • the selected treatment consists of an antidepressant drug monotherapy if the absence of the SNPs is detected.
  • the depression is major depressive disorder (MDD).
  • the individual is an adult (e.g., not a child).
  • the individual can be a human adult.
  • the individual is obese.
  • Obesity can be determined (e.g., identified) if the individual has one of the following conditions: (a) a BMI value greater than 30 kg/m 2 ; b) a waist circumference greater than 40 inches in men, or greater than 35 inches in women; c) a waist-hip ratio above 0.95 for men or above 0.80 for women; or (d) a body fat percentage of at least about 25% in men or at least about 32% in women.
  • the individual is a drug naive individual.
  • the individual is resistant (e.g., has no response or a negative response) to at least one antidepressant drug that is different than the selected antidepressant drug.
  • the selected antidepressant drug to which the individual has not developed resistance can be recommended or administered.
  • the individual has a partial response to at least one antidepressant drug. In such a case, a different or an additional antidepressant drug can be selected, recommended or administered.
  • the sample from the individual is selected from the group consisting of a blood sample, a serum sample, a plasma sample, a urine sample, a buccal sample, a saliva sample and a combination thereof.
  • the present invention provides a method for predicting a positive response to an antidepressant drug therapy in an individual having depression.
  • the method comprises (a) detecting the presence or absence of the following single nucleotide polymorphisms (S Ps) in a sample obtained from the individual: (i) a SNP at position 27 of SEQ ID NO: l comprising at least one thymine "T" allele or the complement thereof for MTHFR (rs 1801 133); (ii) a SNP at position 27 of SEQ ID NO:2 comprising at least one guanine "G" allele or the complement thereof for MTR (rsl 805087); (iii) a SNP at position 27 of SEQ ID NO:3 comprising at least one thymine "T” allele or the complement thereof for GCHl (rs8007267); and (iv) a SNP at position 27 of SEQ ID NO:4 comprising at least one guanine "G" allele or
  • step (b) also comprises predicting a likelihood of non-response to a folate drug if the presence of at least one of the SNPs is detected. In some embodiments, the method further includes administering an antidepressant drug to the individual.
  • the antidepressant drug therapy comprises a selective serotonin reuptake inhibitor (SSRI).
  • SSRI can be selected from the group consisting of fluoxetine, citalopram, paroxetine, escitalopram, sertraline and a combination thereof.
  • the antidepressant drug therapy consists of an antidepressant drug monotherapy if the absence of the SNPs is detected.
  • the depression is major depressive disorder (MDD).
  • the individual is an adult (e.g., not a child).
  • the individual can be a human adult.
  • the individual is obese.
  • Obesity can be determined (e.g., identified) if the individual has one of the following conditions: (a) a BMI value greater than 30 kg/m 2 ; b) a waist circumference greater than 40 inches in men, or greater than 35 inches in women; c) a waist-hip ratio above 0.95 for men or above 0.80 for women; or (d) a body fat percentage of at least about 25% in men or at least about 32% in women.
  • the individual is a drug naive individual.
  • the individual is resistant (e.g., has no response or a negative response) to at least one antidepressant drug that is different than the antidepressant drug predicted to have a positive response.
  • the antidepressant drug predicted to have a positive response to which the individual has not developed resistance can be selected, recommended or administered.
  • the individual has a partial response to at least one antidepressant drug. In such a case, a different or an additional antidepressant drug can be selected, recommended or administered.
  • the sample used in the method described above can be selected from the group consisting of a blood sample, a serum sample, a plasma sample, a urine sample, a buccal sample, a saliva sample and a combination thereof.
  • the present invention provides a method for determining the prognosis of an individual diagnosed with depression and receiving an antidepressant drug therapy.
  • the method comprises (a) detecting the presence or absence of the following single nucleotide polymorphisms (SNPs) in a sample obtained from the individual: (i) a SNP at position 27 of SEQ ID NO: l comprising at least one thymine "T" allele or the complement thereof for MTHFR (rs 1801 133); (ii) a SNP at position 27 of SEQ ID NO:2 comprising at least one guanine "G" allele or the complement thereof for MTR (rsl 805087); (iii) a SNP at position 27 of SEQ ID NO:3 comprising at least one thymine "T” allele or the complement thereof for GCHl (rs8007267); and (iv) a SNP at position 27 of SEQ ID NO:4 comprising at least one guanine "G"
  • SNPs single nu
  • the method also includes predicting a poor prognosis for the individual receiving the antidepressant drug therapy if the presence of any one of the SNPs is detected.
  • a prediction of poor prognosis also includes recommending that the individual receive a non-antidepressant drug.
  • a non-antidepressant drug can be a folate- containing compound.
  • the antidepressant drug therapy comprises a selective serotonin reuptake inhibitor (SSRI).
  • SSRI can be selected from the group consisting of fluoxetine, citalopram, paroxetine, escitalopram, sertraline and a combination thereof.
  • the antidepressant drug therapy consists of an antidepressant drug monotherapy if the absence of the S Ps is detected.
  • the depression is major depressive disorder (MDD).
  • the individual is an adult (e.g., not a child).
  • the individual can be a human adult.
  • the individual is obese.
  • Obesity can be determined (e.g., identified) if the individual has one of the following conditions: (a) a BMI value greater than 30 kg/m 2 ; b) a waist circumference greater than 40 inches in men, or greater than 35 inches in women; c) a waist-hip ratio above 0.95 for men or above 0.80 for women; or (d) a body fat percentage of at least about 25% in men or at least about 32% in women.
  • the sample obtained from the individual is selected from the group consisting of a blood sample, a serum sample, a plasma sample, a urine sample, a buccal sample, a saliva sample and a combination thereof.
  • the present invention is based, in part, upon the surprising discovery that the therapeutic efficacy of drug monotherapy for the treatment of depression, e.g., major depressive disorder (MDD), can be substantially improved by detecting the genotype of certain markers in a biological sample from an individual.
  • the present invention provides methods for selecting an antidepressant drug therapy for the individual.
  • the present invention also provides methods for predicting whether an individual will respond to an antidepressant drug.
  • the present invention provides methods for determining the prognosis of a depressed patient receiving an antidepressant drug.
  • the methods described herein utilize multiple genetic and/or other markers to provide an indication of a patient's projected response to an antidepressant drug monotherapy.
  • the use of the markers provides the ability to distinguish prospective responders from non-responders.
  • the markers enable the determination of patients who are resistant to antidepressant therapy. II. Definitions
  • depression refers to a mental state of depressed mood characterized by feelings of sadness, despair and discouragement.
  • depression is a clinical symptom, and can include, but not limited to, major depressive disorder (including single episode and recurrent), unipolar depression, treatment-refractory depression, resistant depression, anxious depression and dysthymia (also referred to as dysthymic disorder).
  • depression can encompass any major depressive disorder, dysthymic disorder, mood disorders due to medical conditions with depressive features, mood disorders due to medical conditions with major depressive-like episodes, substance-induced mood disorders with depressive features and depressive disorder not otherwise specific as defined by their diagnostic criteria, as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) or any later edition thereof, or the World Health Organization's International Statistical Classification of Diseases and Related Health Problems (ICD-10).
  • sample includes any biological specimen obtained from an individual. Suitable samples for use in the present invention include, without limitation, whole blood, plasma, serum, cerebrospinal fluid, saliva, urine, stool, tears, any other bodily fluid, tissue samples (e.g., biopsy), and cellular extracts thereof (e.g., red blood cellular extract).
  • tissue samples e.g., biopsy
  • cellular extracts thereof e.g., red blood cellular extract
  • the sample is a blood, plasma or serum sample.
  • samples such as serum, saliva, and urine is well known in the art (see, e.g., Hashida et al., J. Clin. Lab. Anal, 11 :267-86 (1997)).
  • samples such as blood, plasma or serum samples can be diluted prior to the analysis of marker levels.
  • the term "marker” or “biomarker” includes any biochemical marker, serological marker, protein markers, genetic marker, metabolic markers, or other clinical characteristic that can be used in the selection of therapy for depression, in the prediction of the probable course and outcome of depression, and/or in the prediction of the likelihood of recovery from the disorder.
  • the markers are utilized in combination with one or more (e.g., a plurality of) statistical analyses to aid or provide a prognosis of depression in an individual.
  • the markers are used to aid or provide a prediction of therapeutic response to a treatment (e.g., antidepressant drug therapy or monotherapy) in an individual diagnosed with depression (e.g., major depressive disorder).
  • the present invention relies, in part, on determining the presence (or absence) or level (e.g., concentration) of at least one marker in a sample obtained from an individual.
  • detecting the presence of at least one marker includes determining the presence of each marker of interest by using any quantitative or qualitative assay known to one of skill in the art.
  • qualitative assays that determine the presence or absence of a particular trait, variable, genotype, and/or biochemical or serological substance are suitable for detecting each marker of interest.
  • quantitative assays that determine the presence or absence of DNA, RNA, protein, antibody, or activity are suitable for detecting each marker of interest.
  • the term "detecting the level of at least one marker” includes determining the level of each marker of interest by using any direct or indirect quantitative assay known to one of skill in the art. In certain instances, quantitative assays that determine, for example, the relative or absolute amount of DNA, RNA, protein, antibody, or activity are suitable for detecting the level of each marker of interest. One skilled in the art will appreciate that any assay useful for detecting the level of a marker is also useful for detecting the presence or absence of the marker.
  • gene refers to the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region, such as the promoter and 3 '-untranslated region, respectively, as well as intervening sequences (introns) between individual coding segments (exons).
  • genotyp refers to the genetic composition of an organism, including, for example, whether a diploid organism is heterozygous or homozygous for one or more variant alleles of interest.
  • polymorphism refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population.
  • a "polymorphic site” refers to the locus at which divergence occurs. Preferred polymorphic sites have at least two alleles, each occurring at a particular frequency in a population.
  • a polymorphic locus may be as small as one base pair (i.e., single nucleotide polymorphism or SNP).
  • Polymorphic markers include restriction fragment length polymorphisms, variable number of tandem repeats (VNTR's), hypervariable regions, mini satellites, dinucleotide repeats, trinucleotide repeats, tetranucleotide repeats, simple sequence repeats, and insertion elements such as Alu.
  • the first identified allele is arbitrarily designated as the reference allele, and other alleles are designated as alternative alleles, "variant alleles," or “variances.”
  • the allele occurring most frequently in a selected population is sometimes referred to as the "wild-type" allele. Diploid organisms may be homozygous or heterozygous for the variant alleles.
  • the variant allele may or may not produce an observable physical or biochemical characteristic ("phenotype") in an individual carrying the variant allele.
  • a variant allele may alter the enzymatic activity of a protein encoded by a gene of interest.
  • single nucleotide polymorphism refers to a change of a single nucleotide with a polynucleotide, including within an allele. This can include the replacement of one nucleotide by another, as well as deletion or insertion of a single nucleotide. Most typically, S Ps are biallelic markers although tri- and tetra-allelic markers can also exist.
  • a nucleic acid molecule comprising SNP AC/CC may include a C allele and an A allele at the polymorphic position, or two C alleles at the polymorphic position.
  • haplotype is used, e.g. the genotype of the SNPs in a single DNA strand that are linked to one another.
  • haplotype can be used to describe a combination of SNP alleles, e.g., the alleles of the SNPs found together on a single DNA molecule.
  • the SNPs in a haplotype can be in linkage disequilibrium with one another.
  • SAM refers to S-adenosyl methionine, commonly known as SAM, or SAM-e, or AdoMet, which is a natural compound found in all living cells.
  • S-Adenosyl methionine is a common cosubstrate involved in methyl group transfers. It is made from adenosine triphosphate (ATP) and methionine by methionine adenosyltransferase. SAM is used in metabolic pathways such as transmethylation, transsulfuration, and aminopropylation.
  • SAH refers to S-adenosylhomocysteine which is formed by the demethylation of S-adenosyl-L-methionine.
  • SAM S-adenosylmethionine
  • SAH S-adenosylhomocysteine
  • SAM/SAH ratio refers to the relative levels of S-adenosyl methionine to S-adenosylhomocysteine. In some instances, a decrease in the SAM/SAH ratio is associated with increased homocysteine in serum and an increase in SAH.
  • 4-HNE refers to 4-hydroxynonenal, or 4-hydroxy-2-nonenal which is an a, ⁇ -unsaturated hydroxyalkenal that is produced by lipid peroxidation in cells.
  • 4-HNE is the primary a, ⁇ -unsaturated hydroxyalkenal formed in this process. It is found throughout body tissue, and in higher quantities during oxidative stress due to the increase in the lipid peroxidation chain reaction in stress events. It appears to play a key role in cell signal transduction in a variety of pathways from cell cycle events to cellular adhesion. 4-HNE is also considered as possible causal agents of numerous diseases, such as chronic inflammation, neurodegenerative diseases, adult respiratory distress syndrome, atherogenesis, diabetes and different types of cancer.
  • hsCRP refers to the high-sensitivity c-reactive protein which is found in, e.g., blood, serum, and plasma. Elevated levels of hsCRP in serum and plasma have been detected in patients with symptoms of depression, as well as patients with an inflammatory disease. For example, it has been reported that major depression is associated with increased levels of hsCRP and inflammatory markers such as IL-6 and TNF-a (see, e.g., Dinan TG. Current Opinion Psychia., 2009, 22(l):32-6).
  • the term "individual,” “subject,” or “patient” are used interchangeably and typically includes humans, but also includes other animals such as, e.g., other primates, rodents, canines, felines, equines, ovines, porcines, and the like.
  • naive individual refers to a subject who has not received a therapeutic drug for the treatment of a disease/disorder, e.g., depression.
  • a disease/disorder e.g., depression.
  • the naive patient with depression has not been administered an SSRI drug, a folate drug or other drug used to treat depression.
  • folate drug refers to a compound containing an effective amount of at least one folate for use in the methods described herein.
  • Folate is a form of the water-soluble vitamin B9.
  • folate encompasses the naturally-occurring form of folate, folic acid (also known as vitamin B9 or folacin) and metabolites or derivatives thereof such as methylfolate, tetrahydrofolate, and methyltetrahydrofolate.
  • the term “folate” can also refer to both pteroic acid monoglutamate (folic acid) and reduced forms such as dihydrofolates and tetrahydrofolates, e.g. 5- formyltetrahydrofolic acid, 5-methyltetrahydrofolic acid, 5, 10-methylenetetrahydrofolic acid, 5, 10-methenyltetrahydrofolic acid, 10-formyltetrahydrofolic acid and tetrahydrofolic acid, polyglutamates thereof, optical isomers thereof (e.g., optically pure natural isomers thereof, and also mixtures of optical isomers such as racemic mixtures), derivatives thereof, pharmaceutically acceptable salts and esters thereof, glucosamine salts thereof, and galactosamine salts thereof.
  • folic acid pteroic acid monoglutamate
  • reduced forms such as dihydrofolates and tetrahydrofolates, e.g. 5- formylte
  • antidepressant or “antidepressant drug” refers to any pharmaceutical agent which treats depression.
  • antidepressant drug administered to the subject in accordance with the methods described herein can be any conventional pharmaceutical agent which is commonly indicated for treating depression.
  • antidepressant drugs include, but are not limited to, selective serotonin reuptake inhibitors (SSRIs), serotonin and dopamine reuptake inhibitors (SDRIs), serotonin-norepinephrine reuptake inhibitors (S RIs), serotonin-noradrenaline-dopamine reuptake inhibitors (S DRIs), norepinephrine-dopamine reuptake inhibitors ( DRIs), norepinephrine (noradrenaline) reuptake inhibitors (NRIs), monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake enhancers (SSREs), melatonergic agonists, tryptamines, tricyclic antidepressants, and atypical antidepressants.
  • SSRIs selective serotonin reuptake inhibitors
  • SDRIs serotonin-norepinephrine reuptake inhibitor
  • drug monotherapy refers to a treatment regimen that includes the use of one therapeutic agent (e.g., drug) or a single class of therapeutic agents during the course of therapy.
  • the agent(s) can be administered once or repeatedly during the course of therapy.
  • drug monotherapy described herein can be administered alone or as part of a combined therapeutic approach with psychotherapy, psychodynamic therapy, cognitive behavior therapy and combinations thereof.
  • antidepressant drug monotherapy refers to a drug treatment regimen consisting of a single antidepressant drug (e.g., an SSRI drug) or a single class of antidepressant drugs (e.g., a combination of SSRIs) during the course of therapy.
  • a single antidepressant drug e.g., an SSRI drug
  • a single class of antidepressant drugs e.g., a combination of SSRIs
  • antidepressant drugs can be used.
  • the antidepressant drug(s) can be administered once or repeated during the course of therapy.
  • treatment refers to preventing the progression of the disease, altering the course of the disorder (for example, but are not limited to, slowing the progression of the disorder), partially reversing a symptom of the disorder or reducing one or more symptoms and/or one or more biochemical markers in a subject, preventing one or more symptoms from worsening or progressing, promoting recovery, and/or improving prognosis.
  • treatment regimen refers to a clinically relevant course of treatment for reducing (decreasing) at least one symptom associated with a disease/disorder, and/or improving the course of the disease/disorder.
  • negative response includes a worsening of a disorder or condition in a patient receiving therapy, such that the patient experiences increased or additional signs or symptoms of the disorder.
  • the term "positive response" includes an improvement in a patient with a disorder or condition, such that the therapy alleviates signs or symptoms of the disorder.
  • a poor prognosis refers to an unlikely prospect of survival and/or recovery from a disease.
  • a poor prognosis can correspond to a higher likelihood that a patient will not survive or will not recover from a specific disease or disorder than the patient surviving or recovering.
  • a poor prognosis for depression can include progressive decline of mental state, increased number of depressed episodes, increased duration of depressed episodes, increased number of depressed episodes, increased severity of depression and the like.
  • the term "good prognosis" includes a likely prospect of survival and/or recovery from a disease.
  • a good prognosis can correspond to a higher likelihood that a patient will survive or will recover from a specific disease or disorder than the patient not surviving or not recovering.
  • a good prognosis for depression can include progressive improvement in mental state as assessed, for example, according to the HAMD28 scale, decreased number of depressed episodes, decreased duration of depressed episodes, decreased number of depressed episodes, decreased severity of depression and the like.
  • the methods described herein are directed to individuals who are diagnosed with depression, e.g., major depressive disorder, or are at risk for depression.
  • Depression can be diagnosed using standard clinical criteria, e.g., the DSM-IV- TR system.
  • the DSM-IV system for diagnosing MDD requires the presence of at least five out of the ten depressive symptoms including depressed mood or irritable, decreased interest or pleasure, significant weight change (5%) or change in appetite, change in sleep (e.g., insomnia or hypersomnia), change in activity, fatigue or loss of energy, guilt or worthlessness, diminished concentration and suicidiality.
  • the symptoms should be represent for at least two weeks and each symptom should be at sufficient severity for nearly every day.
  • depression is evaluated by a clinician using, e.g., the criteria listed in the DSM-IV or efficacy measures (neuropsychological assessments) such as the Hamilton Depression Rating Scale (HAMD-28 or HAMD-7), the Clinical Global Impression (CGI) Scale, the Montgomery-Asberg Depression Rating Scale (MADRS), the Beck Depression Inventory (BDI), the Zung Self-Rating Depression Scale, the Wechsler Depression Rating Scale, the Raskin Depression Rating Scale, the Inventory of Depressive Symptomatology (IDS), and the Quick Inventory of Depressive Symptomatology (QIDS).
  • HAMD-28 or HAMD-7 the Clinical Global Impression Scale
  • MADRS Montgomery-Asberg Depression Rating Scale
  • BDI Beck Depression Inventory
  • Zung Self-Rating Depression Scale the Wechsler Depression Rating Scale
  • the Raskin Depression Rating Scale the Inventory of Depressive Symptomatology (IDS)
  • QIDS Quick Inventory of Depressive Symptomatology
  • measurable lessening of depression includes any clinically significant decline in a measurable marker or symptom, such as measuring markers for depression in the blood, e.g., red blood cell folate, serum folate, serum MTHF, or assessing the degree of depression, e.g., using a neuropsychological assessment.
  • a score of 0-7 on HAMD is typically considered to be normal. Scores of 20 or higher indicate moderate, severe, or very severe depression. Questions 18-21 may be recorded to give further information about the depression (such as whether diurnal 1 variation or paranoid symptoms are present), but are not necessary part of the scale. Thus, a reduction of symptoms can be considered clinically relevant if, e.g., the HAMD score is decreased to under, e.g., 20.
  • a good prognosis for patients diagnosed with depression can include recovery to a non-depressive state, significant and lasting improvement in mental health, fewer intermittent depressive episodes compared to baseline (e.g., after initial episode or time of diagnosis), good compliance with prescribed treatment, higher chance of recovery than no recovery, less frequent depressive episodes compared to baseline (e.g., after initial episode or time of diagnosis), less severe depression as determined by a clinical scale, decreased duration of depressive episodes, early remission as defined as a patient's no longer meeting the criteria for depression according to the DSM, consistency of remission, good clinical response as measured by, e.g., HDRS, CGI-S, and the Hamilton Anxiety Rate Scale (HARS), and improved quality of life after initial depressive episode as measured by a clinical scale.
  • a poor prognosis can include an absence of a good prognosis, a low chance or probability (e.g., ⁇ 20%) of recovery, no improvement in mental health, poor compliance with prescribed treatment, a higher chance of no recovery than recovery, more frequent depressive episodes compared to baseline, more severe depression than initial depressive episode, no remission, no response or partial response to drug therapy, relapse that occurs within 6 months after either response or remission, worsening of quality of life after initial depressive episode, increased duration of actual depressive episodes, change from less severe depression to more severe depression (e.g., from full remission to poor remission, from mild depression to moderate depression, from moderate depression to severe depression without psychotic features or with psychotic features), and progression from single episode to recurrent episodes.
  • a good response to a drug therapy for depression includes a patient achieving remission in the first period, e.g., 6 months, of treatment and remaining in remission until the end of follow-up, e.g., 12 months.
  • no response or non-response represents an absence of a good response.
  • a patient is diagnosed with major depressive disorder if the patient endorses (exhibits or agrees to having) five of nine criteria symptoms, with one of the five being either depressed mood or loss of interest or pleasure.
  • the other criteria symptoms can include significant weight loss or gain, or decrease or increase in appetite nearly every day; fatigue or loss of energy nearly every day; insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; insomnia or hypersomnia nearly every day; feelings of worthlessness or guilt nearly every day; diminished ability to think or concentrate, or indecisiveness nearly every day; and recurrent thought of death or suicidal intent.
  • the symptoms of MDD must be present for a duration of 2 weeks or longer, represent a change from previous functioning, and cause clinically significant distress or impairment in social, occupational or other important areas of functioning.
  • the DSM-IV determines severity of MDD as mild, moderate or severe based on the number of criteria symptoms, the severity of the symptoms, and the degree of functional disability and distress.
  • a mild depressive episode can be characterized by the presence of only five or six depressive symptoms and either mild disability or the capacity to function normally but with substantial and unusual effort.
  • Moderate episodes have a severity that is intermediate between mild and severe. Severe episodes can include the presence of most of the criteria symptoms and observable disability.
  • predicting a positive response to an antidepressant drug therapy in a patient diagnosed with depression such as MDD. Also provided are methods for determining if a patient diagnosed with depression and receiving an antidepressant drug therapy will have a good prognosis.
  • the method of selecting a suitable treatment for an individual with depression is based on the determination that the individual does not carry any of the following SNPs: a SNP at position 27 of SEQ ID NO: l comprising at least one thymine "T" allele or the complement thereof for MTHFR (rs 1801133); a SNP at position 27 of SEQ ID NO:2 comprising at least one guanine "G” allele or the complement thereof for MTR (rsl805087); a SNP at position 27 of SEQ ID NO:3 comprising at least one thymine "T” allele or the complement thereof for GCHl (rs8007267); and a SNP at position 27 of SEQ ID NO:4 comprising at least one guanine "G” allele or the complement thereof for COMT (rs4680) (Table 1). If all the SNPs are absent, the selected or recommended treatment can include an antidepressant drug. In some instances, the treatment consists of an antidepressant
  • a positive response to an antidepressant drug therapy is predicted if the individual does not carry any of the following SNPs: a SNP at position 27 of SEQ ID NO: l comprising at least one thymine "T" allele or the complement thereof for MTHFR (rs 1801133); a SNP at position 27 of SEQ ID NO:2 comprising at least one guanine "G” allele or the complement thereof for MTR (rs 1805087); a SNP at position 27 of SEQ ID NO:3 comprising at least one thymine "T” allele or the complement thereof for GCHl (rs8007267); and a S P at position 27 of SEQ ID NO:4 comprising at least one guanine "G” allele or the complement thereof for COMT (rs4680).
  • the antidepressant drug therapy consists of an antidepressant drug monotherapy.
  • the individual can be diagnosed with a type of depression such as major depressive disorder (MDD).
  • MDD major depressive disorder
  • the depressed individual is obese. Obesity can be determined if the individual has a BMI value greater than 30 kg/m 2 , a waist circumference greater than 40 inches in men or greater than 35 inches in women, a waist-hip ratio above 0.95 for men or above 0.80 for women, or a body fat percentage (%) of at least about 25% in men or at least about 32% in women.
  • the individual is depressed and is obese.
  • the individual is depressed and not obese.
  • the individual has MDD and is obese. Additionally, the individual can be an adult or a non-adult (e.g., child, toddler, adolescent, or teenager).
  • the individual has not received an antidepressant drug. In other embodiments, the individual has not received any therapy for depression.
  • the individual can be treatment-naive. In other instances, the individual is resistant or refractory to a drug therapy, such as an antidepressant drug. In some embodiments, the individual is resistant to an SSRI. If the individual is resistant to one or more antidepressant drugs and does not carry any of the S Ps described herein, an antidepressant drug that the individual is not resistant to can be selected, recommended or administered. For instance, if the individual is resistant to an SSRI, an S RI drug can be given. Alternatively, if the individual is resistant to a particular SSRI drug, a different SSRI drug can be given.
  • the antidepressant drug monotherapy includes one or more (e.g., at least 1, 2, 3, 4, 5, 6 or more) antidepressant drugs from a single (i.e., the same) class of antidepressants.
  • the antidepressant drug monotherapy includes one or more (e.g., at least 1, 2, 3, 4, 5, 6 or more) antidepressant drugs from one or more (e.g., at least 1, 2, 3, 4, 5, 6 or more) different classes of antidepressants.
  • the antidepressant drug monotherapy excludes all non-antidepressant drugs such as folate- containing compounds.
  • the method of selecting folate adjunctive therapy for depression is based on the determination that the subject carries both folate-responsive markers: a SNP in the MTHFR gene (identified by rs!801133) comprising at least one thymine "T" allele or the complement thereof, and a SNP in the MTR gene (identified by rsl 805087) comprising at least one guanine "G" allele or the complement thereof.
  • the method of selecting a suitable treatment for a subject with depression is based on the determination that the subject carries both folate-responsive markers: a SNP in the GCHl gene (identified by rs8007267) comprising at least one thymine "T" allele or the complement thereof, and a SNP in the COMT gene (identified by rs4680) comprising at least one guanine "G" allele or the complement thereof.
  • a folate-containing compound is not selected, recommended or administered, and an antidepressant drug monotherapy is selected, recommended or administered for the treatment of depression.
  • the method for predicting a positive response to an antidepressant drug comprises detecting the absence of the MTHR variant allele, the MTR variant allele, the GCHl variant allele and the COMT variant allele.
  • the absence of the SNPs MTHFR 677 CT/TT, MTR 2756 AG/GG, GCHl TC/TT and COMT Vall58Met AG/GG indicate that the subject will have a positive response to the antidepressant drug.
  • the subject is predicted to have a likelihood of non-response to a folate-containing compound if the presence of one or more of the following SNPs are detected: SNPs MTHFR 677 CT/TT, MTR 2756 AG/GG, GCHl TC/TT and COMT Vall58Met AG/GG. In some instances, it is recommended that the depressed subject receive antidepressant monotherapy.
  • the subject has not received any drug therapy for depression prior to the drug selection.
  • the subject is resistant to an antidepressant drug. If drug resistance is known or detected, a different antidepressant drug in the same class or different class can be selected for the subject.
  • the method for determining a good prognosis of a depressed subject receiving an antidepressant drug comprises detecting the absence of the MTHFR variant allele, the MTR variant allele, the GCHl variant allele and the COMT variant allele.
  • the absence of MTHFR 677 CT/TT, MTR 2756 AG/GG, GCHl TC/TT and COMT Val l58Met AG/GG indicates that the subject will have a good prognosis on antidepressant monotherapy.
  • the presence of the SNP pair of MTHFR 677 CT/TT and MTR 2756 AG/GG and the presence of the SNP pair of GCHl TC/TT and COMT Vall58Met AG/GG indicates that the subject will have a poor prognosis on antidepressant monotherapy.
  • MTHFR variant includes a nucleotide sequence of a MTHFR gene containing one or more changes as compared to the wild-type MTHFR gene or an amino acid sequence of a MTHFR polypeptide containing one or more changes as compared to the wild-type MTHFR polypeptide sequence.
  • the absence of the MTHFR variant allele refers to the absence of at least one thymine "T" allele or the complement thereof at the S P locus for the MTHFR gene corresponding to rsl801133 or at position 27 of SEQ ID NO: l .
  • the absence of the MTHFR variant allele refers to the presence of two cytosine "C" alleles or the complement thereof at the SNP locus for the MTHFR gene corresponding to rsl 801133 or at positions 27 of SEQ ID NO: l .
  • the presence of the MTHFR variant allele can refer to the presence of at least one thymine "T" allele or the complement thereof at the SNP locus for the MTHFR gene corresponding to rsl 801133 or at position 27 of SEQ ID NO: l .
  • the presence of the heterozygous or homozygous MTHFR variant can be denoted as MTHFR 677 CT/TT.
  • MTHFR also known as EC 1.5.1.20, has been localized to human chromosome 1 (lp.36.22).
  • Gene location information for MTHFR is set forth in, e.g., GenelD: 4524.
  • the mRNA (coding) and polypeptide sequences of human MTHFR are set forth in, e.g., NM_005957.4 and NP_005948.3, respectively.
  • sequence of human chromosome 1, GRCh38 primary reference assembly, which includes MTHFR is set forth in, e.g., GenBank Accession No. NC_000001.11.
  • sequence of MTHFR from other species can be found in the GenBank database.
  • the rsl801133 SNP that finds use in the methods of the present invention is located at nucleotide position 677 of NM_005957.4, as a C to T transition.
  • the presence/absence of the MTHFR rsl801133 SNP and other variants can be detected, for example, by allelic discrimination assays or sequence analysis.
  • allelic variants such as SNPs in the 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) gene is particularly useful in the present invention.
  • the term "MTR variant” or variants thereof includes a nucleotide sequence of a MTR gene containing one or more changes as compared to the wild-type MTR gene or an amino acid sequence of a MTR polypeptide containing one or more changes as compared to the wild-type MTR polypeptide sequence.
  • the absence of the MTR variant allele refers to the absence of at least one guanine "G" allele or the complement thereof at the SNP locus for the MTR gene corresponding to rsl 805087 or at position 27 of SEQ ID NO:2.
  • the absence of the MTR variant allele can refer to the presence of two adenine "A" alleles or the complement thereof at the SNP locus for the MTR gene corresponding to rsl 805087 or at position 27 of SEQ ID NO:2.
  • the presence of the MTR variant allele can refer to the presence of at least one guanine "G" allele or the complement thereof at the SNP locus for the MTR gene corresponding to rsl805087 or at position 27 of SEQ ID NO:2.
  • the presence of the heterozygous or homozygous MTR variant can be denoted as MTR 2756 AG/GG.
  • MTR also known as EC 2.1.1.13, has been localized to human chromosome 1 (lq43).
  • Gene location information for MTR is set forth in, e.g., GenelD: 4548.
  • the mRNA (coding) and polypeptide sequences of human MTR are set forth in, e.g., EMBL No. AAI36441.1 and UniProt No. Q99707, respectively.
  • sequence of human chromosome 1, GRCh38 primary reference assembly, which includes MTR is set forth in, e.g., GenBank Accession No. NC 000001.11.
  • sequence of MTR from other species can be found in the GenBank database.
  • the rsl 805087 SNP that finds use in the methods of the present invention is located at nucleotide position 2756 of AAI36441.1, as an A to G transition.
  • the presence/absence of the MTR rsl 805087 SNP and other variants can be detected, for example, by allelic discrimination assays or sequence analysis.
  • allelic variants such as SNPs in the GTP cyclohydrolase 1 (GCH1) gene
  • GCH1 variant includes a nucleotide sequence of a GCHl gene containing one or more changes as compared to the wild-type GCH1 gene or an amino acid sequence of a GCHl polypeptide containing one or more changes as compared to the wild-type GCHl polypeptide sequence.
  • the absence of the GCHl variant allele refers to the absence of at least one thymine "T" allele or the complement thereof at the SNP locus for the GCHl gene corresponding to rs8007267 or at position 27 of SEQ ID NO:3.
  • the absence of the GCHl variant allele can refer to the presence of two cytosine "C” alleles or the complement thereof at the SNP locus for the GCHl gene corresponding to rs8007267 or at position 27 of SEQ ID NO:3.
  • the presence of the GCHl variant allele can refer to the presence of at least one thymidine "T" allele or the complement thereof at the SNP locus for the GCHl gene corresponding to rs8007267 or at position 27 of SEQ ID NO:3.
  • the presence of the heterozygous or homozygous GCHl variant can be denoted as GCHl TC/TT.
  • GCHl also known as EC 3.5.4.16, has been localized to human chromosome 14 (14q22.2).
  • Gene location information for GCHl is set forth in, e.g., GenelD: 2643.
  • the mRNA (coding) and polypeptide sequences of human GCHl are set forth in, e.g., NCBI RefSeq No. NM_001024024.1 and NP_001019195, respectively.
  • sequence of human chromosome 14, GRCh38 primary reference assembly, which includes GCHl is set forth in, e.g., GenBank Accession No. NC_000014.8.
  • sequence of GCHl from other species can be found in the GenBank database.
  • the rs8007267 SNP that finds use in the methods of the present invention is located in the GCHl gene as a C to T transition.
  • the presence/absence of the GCHl rs8007267 SNP and other variants can be detected, for example, by allelic discrimination assays or sequence analysis.
  • allelic variants such as SNPs in the catechol-O-methyltransferase (COMT) gene is particularly useful in the present invention.
  • the term "COMT variant” or variants thereof includes a nucleotide sequence of a COMT gene containing one or more changes as compared to the wild-type COMT gene or an amino acid sequence of a COMT polypeptide containing one or more changes as compared to the wild-type COMT polypeptide sequence.
  • the absence of the COMT variant allele refers to the absence of at least one guanine "G" allele or the complement thereof at the SNP locus for the COMT gene corresponding to rs4680 or at position 27 of SEQ ID NO:4.
  • the absence of the COMT variant allele can refer to the presence of two adenine "T” alleles or the complement thereof at the SNP locus for the COMT gene corresponding to rs4680 or at position 27 of SEQ ID NO:4.
  • he presence of the COMT variant allele can refer to the presence of at least one guanine "G” allele or the complement thereof at the SNP locus for the COMT gene corresponding to rs4680 or at position 27 of SEQ ID NO:4.
  • COMT Vall58Met AG/GG The presence of the heterozygous or homozygous COMT variant can be denoted as COMT Vall58Met AG/GG.
  • COMT also known as EC 2.1.1.6, has been localized to human chromosome 22 (22ql 1.21).
  • Gene location information for COMT is set forth in, e.g., GenelD: 1312.
  • the mRNA (coding) and polypeptide sequences of human COMT are set forth in, e.g., NCBI RefSeq No. NM_000754.3 and NP_000745, respectively.
  • sequence of human chromosome 22, GRCh38 primary reference assembly which includes COMT, is set forth in, e.g., GenBank Accession No. NC_000022.11.
  • sequence of COMT from other species can be found in the GenBank database.
  • the rs4680 SNP that finds use in the methods of the present invention is located in the COMT gene as an A to G transition.
  • the presence/absence of the COMT rs4680 SNP and other variants can be detected, for example, by allelic discrimination assays or sequence analysis.
  • a method for determining whether a subject is homozygous for a polymorphism, heterozygous for a polymorphism, or lacking the polymorphism altogether is encompassed.
  • a method to detect the C to T variance at position 27 of SEQ ID NO: l corresponding to a SNP of the MTHFR gene; rsl801133
  • a method for determining the allele e.g., heterozygous for the C- and T-alleles, homozygous for the C-allele, or homozygous for the T-allele
  • a variety of means can be used to genotype an individual at a polymorphic site in a gene or any other genetic marker described herein to determine whether a sample (e.g., a nucleic acid sample) contains a specific variant allele or haplotype.
  • a sample e.g., a nucleic acid sample
  • enzymatic amplification of nucleic acid from an individual can be conveniently used to obtain nucleic acid for subsequent analysis.
  • the presence of a specific variant allele or haplotype in one or more genetic markers of interest can also be determined directly from the individual's nucleic acid without enzymatic amplification.
  • an individual is genotyped at the MTHFR, MTR, GCH1 and COMT loci.
  • nucleic acid means a polynucleotide such as a single- or double-stranded DNA or RNA molecule including, for example, genomic DNA, cDNA and mRNA. This term encompasses nucleic acid molecules of both natural and synthetic origin as well as molecules of linear, circular, or branched configuration representing either the sense or antisense strand, or both, of a native nucleic acid molecule.
  • nucleic acids can be unpurified, purified, or attached, for example, to a synthetic material such as a bead or column matrix.
  • Material containing nucleic acid is routinely obtained from individuals. Such material is any biological matter from which nucleic acid can be prepared. As non-limiting examples, material can be whole blood, serum, plasma, urine, feces, saliva, synovial fluid, tears, mucus, a cheek swab, sputum, or other bodily fluid or tissue that contains nucleic acid.
  • a method of the present invention is practiced with whole blood, serum, plasma, urine, saliva or a buccal sample, which can be obtained readily by non-invasive means and used to prepare genomic DNA.
  • genotyping involves amplification of an individual's nucleic acid using the polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • Use of PCR for the amplification of nucleic acids is well known in the art ⁇ see, e.g., Mullis et al. (Eds.), The Polymerase Chain Reaction, Birkhauser, Boston, (1994)).
  • PCR amplification is performed using one or more fluorescently labeled primers.
  • PCR amplification is performed using one or more labeled or unlabeled primers that contain a DNA minor groove binder.
  • any of a variety of different primers can be used to amplify an individual's nucleic acid by PCR in order to determine the presence of a variant allele in one or more genes or loci or other genetic marker in a method of the invention.
  • loci include the human MTHFR, MTR, GCH1 and COMT loci.
  • the PCR primers can be used to amplify specific regions of the MTHFR locus, such as the polymorphism at rsl801133.
  • additional primers for PCR analysis can be designed based on the sequence flanking the polymorphic site(s) of interest in the MTHFR locus or other genetic markers ⁇ e.g., the MTR locus at rsl 805087, GCH1 locus at rs8007267 and COMT locus at rs4680).
  • a sequence primer can contain from about 15 to about 30 nucleotides of a sequence upstream or downstream of the polymorphic site of interest in the MTHFR locus, MTR locus, GCH1 locus or COMT locus.
  • Such primers generally are designed to have sufficient guanine and cytosine content to attain a high melting temperature which allows for a stable annealing step in the amplification reaction.
  • Several computer programs, such as Primer Select, are available to aid in the design of PCR primers.
  • a TaqMan ® allelic discrimination assay available from Applied Biosystems can be useful for genotyping an individual at a polymorphic site and thereby determining the presence of a particular variant allele or haplotype in the MTHFR locus, MTR locus, GCH1 locus or COMT locus. In a TaqMan ® allelic discrimination assay, a specific fluorescent dye- labeled probe for each allele is constructed.
  • the probes contain different fluorescent reporter dyes such as FAM and VIC to differentiate amplification of each allele.
  • each probe has a quencher dye at one end which quenches fluorescence by fluorescence resonance energy transfer.
  • each probe anneals specifically to complementary sequences in the nucleic acid from the individual.
  • the 5' nuclease activity of Taq polymerase is used to cleave only probe that hybridizes to the allele. Cleavage separates the reporter dye from the quencher dye, resulting in increased fluorescence by the reporter dye.
  • the fluorescence signal generated by PCR amplification indicates which alleles are present in the sample.
  • Minor groove binder include, but are not limited to, compounds such as dihydrocyclopyrroloindole tripeptide (DPI3).
  • Sequence analysis can also be useful for genotyping an individual according to the methods described herein to determine the presence of a particular variant allele or haplotype in the MTHFR locus at rs 1801133 or the other genetic markers ⁇ e.g., the MTR locus at rsl805087, GCH1 locus at rs8007267 and COMT locus at rs4680).
  • a variant allele of interest can be detected by sequence analysis using the appropriate primers, which are designed based on the sequence flanking the polymorphic site of interest in the MTHFR, MTR, GCH1 and COMT loci or other genetic markers.
  • Additional or alternative sequence primers can contain from about 15 to about 30 nucleotides of a sequence that corresponds to a sequence about 40 to about 400 base pairs upstream or downstream of the polymorphic site of interest in one or more of the MTHFR, MTR, GCH1 and COMT loci, or another genetic marker.
  • Such primers are generally designed to have sufficient guanine and cytosine content to attain a high melting temperature which allows for a stable annealing step in the sequencing reaction.
  • sequence analysis includes any manual or automated process by which the order of nucleotides in a nucleic acid is determined.
  • sequence analysis can be used to determine the nucleotide sequence of a sample of DNA.
  • sequence analysis encompasses, without limitation, chemical and enzymatic methods such as dideoxy enzymatic methods including, for example, Maxam-Gilbert and Sanger sequencing as well as variations thereof.
  • sequence analysis further encompasses, but is not limited to, capillary array DNA sequencing, which relies on capillary electrophoresis and laser-induced fluorescence detection and can be performed using instruments such as the MegaBACE 1000 or ABI 3700.
  • sequence analysis encompasses thermal cycle sequencing ⁇ see, Sears et al, Biotechniques 13 :626-633 (1992)); solid-phase sequencing ⁇ see, Zimmerman et al, Methods Mol Cell Biol. 3 :39-42 (1992); and sequencing with mass spectrometry, such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry ⁇ see, MALDI-TOF MS; Fu et al, Nature Biotech. 16:381-384 (1998)).
  • sequence analysis further includes, but is not limited to, sequencing by hybridization (SBH), which relies on an array of all possible short oligonucleotides to identify a segment of sequence ⁇ see, Chee et al, Science 274:610-614 (1996); Drmanac et al, Science 260: 1649-1652 (1993); and Drmanac et al, Nature Biotech. 16:54-58 (1998)).
  • SBH sequencing by hybridization
  • Electrophoretic analysis also can be useful in genotyping an individual according to the methods of the present invention to determine the presence of a particular variant allele or haplotype in the MTHFR, MTR, GCH1 and COMT loci, or another genetic marker.
  • "Electrophoretic analysis” as used herein in reference to one or more nucleic acids such as amplified fragments includes a process whereby charged molecules are moved through a stationary medium under the influence of an electric field. Electrophoretic migration separates nucleic acids primarily on the basis of their charge, which is in proportion to their size, with smaller molecules migrating more quickly.
  • electrophoretic analysis includes, without limitation, analysis using slab gel electrophoresis, such as agarose or polyacrylamide gel electrophoresis, or capillary electrophoresis.
  • Capillary electrophoretic analysis generally occurs inside a small-diameter (50-100 m) quartz capillary in the presence of high (kilovolt-level) separating voltages with separation times of a few minutes.
  • nucleic acids are conveniently detected by UV absorption or fluorescent labeling, and single-base resolution can be obtained on fragments up to several hundred base pairs.
  • Restriction fragment length polymorphism (RFLP) analysis can also be useful for genotyping an individual according to the methods of the present invention to determine the presence of a particular variant allele or haplotype in the MTHFR, MTR, GCHl and COMT loci or other genetic marker ⁇ see, Jarcho et al. in Dracopoli et al, Current Protocols in Human Genetics pages 2.7.1-2.7.5, John Wiley & Sons, New York; Innis et al, (Ed.), PCR Protocols, San Diego: Academic Press, Inc. (1990)).
  • restriction fragment length polymorphism analysis includes any method for distinguishing polymorphic alleles using a restriction enzyme, which is an endonuclease that catalyzes degradation of nucleic acid following recognition of a specific base sequence, generally a palindrome or inverted repeat.
  • a restriction enzyme which is an endonuclease that catalyzes degradation of nucleic acid following recognition of a specific base sequence, generally a palindrome or inverted repeat.
  • RFLP analysis depends upon an enzyme that can differentiate a variant allele from a wild-type or other allele at a polymorphic site.
  • allele-specific oligonucleotide hybridization can be useful for genotyping an individual in the methods described herein to determine the presence of a particular variant allele or haplotype in t e MTHFR, MTR, GCHl and COMT loci, or another genetic marker. Allele-specific oligonucleotide hybridization is based on the use of a labeled oligonucleotide probe having a sequence perfectly complementary, for example, to the sequence encompassing the variant allele.
  • the variant allele-specific probe hybridizes to a nucleic acid containing the variant allele but does not hybridize to the one or more other alleles, which have one or more nucleotide mismatches as compared to the probe.
  • a second allele-specific oligonucleotide probe that matches an alternate ⁇ e.g., wild-type) allele can also be used.
  • the technique of allele-specific oligonucleotide amplification can be used to selectively amplify, for example, a variant allele by using an allele-specific oligonucleotide primer that is perfectly complementary to the nucleotide sequence of the variant allele but which has one or more mismatches as compared to other alleles (Mullis et al, supra).
  • an allele-specific oligonucleotide primer that is perfectly complementary to the nucleotide sequence of the variant allele but which has one or more mismatches as compared to other alleles.
  • the one or more nucleotide mismatches that distinguish between the variant allele and other alleles are often located in the center of an allele-specific oligonucleotide primer to be used in the allele- specific oligonucleotide hybridization.
  • an allele-specific oligonucleotide primer to be used in PCR amplification generally contains the one or more nucleotide mismatches that distinguish between the variant and other alleles at the 3' end of the primer.
  • a heteroduplex mobility assay is another well-known assay that can be used for genotyping in the methods of the present invention to determine the presence/absence of a particular variant allele or haplotype in t e MTHFR, MTR, GCHl and COMT loci, or another genetic marker.
  • HMA is useful for detecting the absence of a variant allele since a DNA duplex carrying a mismatch has reduced mobility in a polyacrylamide gel compared to the mobility of a perfectly base-paired duplex ⁇ see, Delwart et al, Science, 262: 1257-1261 (1993); White et al, Genomics, 12:301-306 (1992)).
  • SSCP single strand conformational polymorphism
  • Denaturing gradient gel electrophoresis can also be useful in the methods of the invention to determine the presence/absence of a particular variant allele or haplotype in the MTHFR, MTR, GCHl and COMT loci, or another genetic marker.
  • double- stranded DNA is electrophoresed in a gel containing an increasing concentration of denaturant; double-stranded fragments made up of mismatched alleles have segments that melt more rapidly, causing such fragments to migrate differently as compared to perfectly complementary sequences ⁇ see, Sheffield et al, "Identifying DNA Polymorphisms by Denaturing Gradient Gel Electrophoresis" in Innis et al, supra, 1990).
  • the methods of the present invention provide information regarding the likelihood of a positive response to antidepressant drug therapy in patients with depression, e.g., major depressive disorder. Also, the methods provide information regarding a good prognosis of a depressed subject receiving antidepressant drug therapy, e.g., antidepressant drug monotherapy (e.g., by determining the absence of the variant alleles of genes such as, but not limited to, the MTHFR, MTR, GCH1 and COMT loci) can be practiced using one or any combination of the well-known genotyping assays described above or other assays known in the art.
  • antidepressant drug monotherapy e.g., by determining the absence of the variant alleles of genes such as, but not limited to, the MTHFR, MTR, GCH1 and COMT loci
  • the presence or absence of a variant allele in a genetic marker can be determined using an assay described herein.
  • Assays that can be used to determine variant allele status include, but are not limited to, electrophoretic analysis assays, restriction length polymorphism analysis assays, sequence analysis assays ⁇ e.g., Sanger sequencing, pyrosequencingTM and next-generation sequencing), hybridization analysis assays, PCR analysis assays, allele-specific hybridization, oligonucleotide ligation allele-specific elongation/ligation, allele-specific amplification, single-base extension, molecular inversion probe, invasive cleavage, selective termination, restriction length polymorphism, sequencing, single strand conformation polymorphism (SSCP), single strand chain polymorphism, mismatch-cleaving, denaturing gradient gel electrophoresis, melting-curve FRET hybridization, fluorescent polarization, INVADER ® assay, SNP microarrays, and combinations thereof.
  • the present invention provides methods for selecting treatment for depression or determining the likelihood of a positive response or a good prognosis to treatment with antidepressant drug therapy (e.g., antidepressant drug monotherapy) by detecting the absence of the MTHFR, MTR, GCH1 and COMT variant alleles (e.g., S Ps) and applying a statistical analysis such as quantile analysis or a learning statistical classifier system to the genotype(s) detected at the MTHFR, MTR, GCH1 and COMT loci and/or to the presence of one or more clinical factors, e.g., drug response.
  • antidepressant drug therapy e.g., antidepressant drug monotherapy
  • the use of statistical analyses in the methods of the present invention advantageously provide improved sensitivity, specificity, negative predictive value, positive predictive value, and/or overall accuracy for selecting treatment for depression or predicting or identifying the probability that a subject with depression will respond to treatment with an antidepressant drug therapy.
  • the term "statistical analysis” or “statistical algorithm” or “statistical process” includes any of a variety of statistical methods and models used to determine relationships between variables.
  • the variables are the presence, level, or genotype of at least one marker of interest. Any number of markers can be analyzed using a statistical analysis described herein. For example, the presence or level of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, or more markers can be included in a statistical analysis.
  • logistic regression is used.
  • linear regression is used.
  • the statistical analyses comprise a quantile measurement of one or more markers, e.g., within a given population, as a variable.
  • Quantiles are a set of "cut points" that divide a sample of data into groups containing (as far as possible) equal numbers of observations. For example, quartiles are values that divide a sample of data into four groups containing (as far as possible) equal numbers of observations. The lower quartile is the data value a quarter way up through the ordered data set; the upper quartile is the data value a quarter way down through the ordered data set.
  • Quintiles are values that divide a sample of data into five groups containing (as far as possible) equal numbers of observations.
  • the present invention can also include the use of percentile ranges of marker levels (e.g., tertiles, quartile, quintiles, etc.), or their cumulative indices (e.g., quartile sums of marker levels to obtain quartile sum scores (QSS), etc.) as variables in the statistical analyses (just as with continuous variables).
  • the statistical analyses comprise one or more learning statistical classifier systems.
  • learning statistical classifier system includes a machine learning algorithmic technique capable of adapting to complex data sets (e.g., panel of markers of interest) and making decisions based upon such data sets.
  • a single learning statistical classifier system such as a decision/classification tree (e.g., random forest (RF) or classification and regression tree (C&RT)) is used.
  • RF random forest
  • C&RT classification and regression tree
  • 2, 3, 4, 5, 6, 7, 8, 9, 10, or more learning statistical classifier systems are used, preferably in tandem.
  • Examples of learning statistical classifier systems include, but are not limited to, those using inductive learning (e.g., decision/classification trees such as random forests, classification and regression trees (C&RT), boosted trees, etc.), Probably Approximately Correct (PAC) learning, connectionist learning (e.g., neural networks (NN), artificial neural networks (ANN), neuro fuzzy networks (NFN), network structures, perceptrons such as multi-layer perceptrons, multi-layer feed-forward networks, applications of neural networks, Bayesian learning in belief networks, etc.), reinforcement learning (e.g., passive learning in a known environment such as naive learning, adaptive dynamic learning, and temporal difference learning, passive learning in an unknown environment, active learning in an unknown environment, learning action-value functions, applications of reinforcement learning, etc.), and genetic algorithms and evolutionary programming.
  • inductive learning e.g., decision/classification trees such as random forests, classification and regression trees (C&RT), boosted trees, etc.
  • PAC Probably Approximately Correct
  • connectionist learning e.g., neural networks
  • learning statistical classifier systems include support vector machines (e.g., Kernel methods), multivariate adaptive regression splines (MARS), Levenberg- Marquardt algorithms, Gauss-Newton algorithms, mixtures of Gaussians, gradient descent algorithms, and learning vector quantization (LVQ).
  • support vector machines e.g., Kernel methods
  • MMARS multivariate adaptive regression splines
  • Levenberg- Marquardt algorithms e.g., Gauss-Newton algorithms
  • mixtures of Gaussians e.g., Gauss-Newton algorithms
  • mixtures of Gaussians e.g., gradient descent algorithms
  • LVQ learning vector quantization
  • Random forests are learning statistical classifier systems that are constructed using an algorithm developed by Leo Breiman and Adele Cutler. Random forests use a large number of individual decision trees and decide the class by choosing the mode (i.e., most frequently occurring) of the classes as determined by the individual trees. Random forest analysis can be performed, e.g., using the RandomForests software available from Salford Systems (San Diego, CA). See, e.g., Breiman, Machine Learning, 45:5-32 (2001); and at the website stat-www.berkeley.edu/users/breiman/RandomForests/cc_home.htm, for a description of random forests.
  • Classification and regression trees represent a computer intensive alternative to fitting classical regression models and are typically used to determine the best possible model for a categorical or continuous response of interest based upon one or more predictors.
  • Classification and regression tree analysis can be performed, e.g., using the C&RT software available from Salford Systems or the Statistica data analysis software available from StatSoft, Inc. (Tulsa, OK).
  • C&RT software available from Salford Systems
  • Statistica data analysis software available from StatSoft, Inc. (Tulsa, OK).
  • a description of classification and regression trees is found, e.g., in Breiman et al. "Classification and Regression Trees," Chapman and Hall, New York (1984); and Steinberg et al, “CART: Tree- Structured Non-Parametric Data Analysis,” Salford Systems, San Diego, (1995).
  • Neural networks are interconnected groups of artificial neurons that use a mathematical or computational model for information processing based on a connectionist approach to computation.
  • neural networks are adaptive systems that change their structure based on external or internal information that flows through the network.
  • Specific examples of neural networks include feed-forward neural networks such as perceptrons, single-layer perceptrons, multi-layer perceptrons, backpropagation networks, ADALINE networks, MADALINE networks, Learnmatrix networks, radial basis function (RBF) networks, and self-organizing maps or Kohonen self-organizing networks; recurrent neural networks such as simple recurrent networks and Hopfield networks; stochastic neural networks such as Boltzmann machines; modular neural networks such as committee of machines and associative neural networks; and other types of networks such as instantaneously trained neural networks, spiking neural networks, dynamic neural networks, and cascading neural networks.
  • feed-forward neural networks such as perceptrons, single-layer perceptrons, multi-layer perceptrons, backpropagation networks, ADALINE networks
  • Neural network analysis can be performed, e.g., using the Statistica data analysis software available from StatSoft, Inc. See, e.g., Freeman et al., In “Neural Networks: Algorithms, Applications and Programming Techniques," Addison- Wesley Publishing Company (1991); Zadeh, Information and Control, 8:338-353 (1965); Zadeh, “IEEE Trans, on Systems, Man and Cybernetics," 3 :28-44 (1973); Gersho et al., In “Vector Quantization and Signal Compression,” Kluywer Academic Publishers, Boston, Dordrecht, London (1992); and Hassoun, “Fundamentals of Artificial Neural Networks,” MIT Press, Cambridge, Massachusetts, London (1995), for a description of neural networks.
  • Support vector machines are a set of related supervised learning techniques used for classification and regression and are described, e.g., in Cristianini et al, "An Introduction to Support Vector Machines and Other Kernel-Based Learning Methods," Cambridge University Press (2000). Support vector machine analysis can be performed, e.g., using the SVM /3 ⁇ 4Ai software developed by Thorsten Joachims (Cornell University) or using the LIBSVM software developed by Chih-Chung Chang and Chih-Jen Lin (National Taiwan University).
  • sensitivity refers to the probability that a predictive method of the present invention gives a positive result when the sample is positive, e.g., having the predicted therapeutic response to an antidepressant drug monotherapy in an individual with depression.
  • Sensitivity is calculated as the number of true positive results divided by the sum of the true positives and false negatives. Sensitivity essentially is a measure of how well the present invention correctly identifies those with depression who have the predicted therapeutic response to an antidepressant drug monotherapy.
  • the statistical methods and models can be selected such that the sensitivity is at least about 60%, and can be, e.g., at least about 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
  • the term "specificity" refers to the probability that a predictive method of the present invention gives a negative result when the sample is not positive, e.g., not having the predicted therapeutic response to an antidepressant drug monotherapy in an individual with depression. Specificity is calculated as the number of true negative results divided by the sum of the true negatives and false positives. Specificity essentially is a measure of how well the present invention excludes those with depression who do not have the predicted therapeutic response to an antidepressant drug monotherapy.
  • the statistical methods and models can be selected such that the specificity is at least about 60%, and can be, e.g., at least about 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
  • negative predictive value refers to the probability that an individual identified as having depression is not having the predicted therapeutic response to an antidepressant drug monotherapy. Negative predictive value can be calculated as the number of true negatives divided by the sum of the true negatives and false negatives. Negative predictive value is determined by the characteristics of the diagnostic or prognostic method as well as the prevalence of the disease in the population analyzed.
  • the statistical methods and models can be selected such that the negative predictive value in a population having a disease prevalence is in the range of about 70% to about 99% and can be, for example, at least about 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
  • the term "positive predictive value” or "PPV" refers to the probability that an individual identified as having depression is having the predicted therapeutic response to an antidepressant drug monotherapy. Positive predictive value can be calculated as the number of true positives divided by the sum of the true positives and false positives.
  • Positive predictive value is determined by the characteristics of the predictive method as well as the prevalence of the disease in the population analyzed.
  • the statistical methods and models can be selected such that the positive predictive value in a population having a disease prevalence is in the range of about 70% to about 99% and can be, for example, at least about 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
  • Predictive values are influenced by the prevalence of the disease in the population analyzed.
  • the statistical methods and models can be selected to produce a desired clinical parameter for a clinical population with a particular depression prevalence.
  • statistical methods and models can be selected for a depression prevalence of up to about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70%), which can be seen, e.g., in a clinician's office such as a psychiatrist's office or a general practitioner's office.
  • the term “overall agreement” or “overall accuracy” refers to the accuracy with which a method of the present invention predicts response to an antidepressant drug monotherapy. Overall accuracy is calculated as the sum of the true positives and true negatives divided by the total number of sample results and is affected by the prevalence of depression in the population analyzed.
  • the statistical methods and models can be selected such that the overall accuracy in a patient population having a disease prevalence is at least about 40%, and can be, e.g., at least about 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
  • a physical biomarker e.g., obesity indicator
  • obesity is defined as, e.g., a BMI value of at least about 30 kg/m 2 or greater; a waist circumference greater than 40 inches (or greater than 120 cm) in men, or greater than 35 inches (or greater than 88 cm) in women; a waist-hip ratio above 0.95 for men or above 0.80 for women; and/or a body fat percentage of at least about 25% in men or at least about 32% in women.
  • an antidepressant drug is selected, recommended and/or administered to treat depression.
  • the methods provided herein can comprise determining if the human subject is obese or not. If the human subject is determined to be obese, then the human subject is selected for and optionally administered with a treatment regimen comprising an effective amount of a folate drug.
  • Methods of determining obesity in a human subject are known in the art and can include, but are not limited to, body mass index (BMI) measurement, measurement of abdominal fat (e.g., by waist circumference or waist-hip ratio), measurement of body fat, skinfold thickness, underwater weighing (densitometry), air- displacement plethysmography, computerized tomography (CT) and magnetic resonance imaging (MRI), and dual energy X-ray absorptiometry (DEXA), and any combinations thereof.
  • BMI body mass index
  • CT computerized tomography
  • MRI magnetic resonance imaging
  • DEXA dual energy X-ray absorptiometry
  • the methods also include measuring the level of metabolites, such as SAM, SAH and/or 4-HNE, in a sample, e.g., blood serum, plasma, or CSF sample, from a subject having or at risk for depression.
  • a sample e.g., blood serum, plasma, or CSF sample
  • levels of metabolites e.g., SAM, SAH, and/or 4-HNE
  • MS mass spectrometry
  • the biological sample is infused directly into the mass spectrometer which provides both separation and detection of metabolites (e.g., SAM, SAH, and/or 4-HNE).
  • the target metabolite e.g., SAM, SAH and/or 4-HNE
  • the target metabolite can be optionally separated (e.g., prior to detection) from a biological sample by gas chromatography (GC), e.g., when interfaced with mass spectrometry (GC-MS), and/or high performance liquid chromatography (HPLC), and/or capillary electrophoresis (CE).
  • GC gas chromatography
  • HPLC high performance liquid chromatography
  • CE capillary electrophoresis
  • a patient is selected to receive an antidepressant drug therapy, such as an antidepressant drug monotherapy.
  • the monotherapy includes receiving one or more drugs from a single class of antidepressants.
  • the antidepressant drug monotherapy includes receiving one or more (e.g., 1, 2, 3, 4, 5, 6 or more) drugs from one or more (e.g., 1, 2, 3, 4, 5, 6 or more) different classes of antidepressants.
  • the antidepressant drug monotherapy is a selective serotonin reuptake inhibitor (SSRI).
  • SSRI selective serotonin reuptake inhibitor
  • the antidepressant drug monotherapy is from a non-SSRI class of antidepressants.
  • the subject can be administered a different antidepressant drug from the same class or from a different class of antidepressant drugs.
  • a specific antidepressant drug or a specific class of antidepressant drugs the subject can be administered a different antidepressant drug from the same class or from a different class of antidepressant drugs.
  • an SSRI drug e.g., fluoxetine
  • another SSRI drug e.g., citalopram
  • an SNRI or SDRI drug may be selected or recommended for the subject and/or administered.
  • the subject is not resistant to an antidepressant drug or a class of antidepressant drugs. In some instances, the subject has never received an antidepressant drug. In other instances, the subject has never received any drug therapy for the treatment of depression. [0113] Various types or classes of antidepressants are known and commercially available.
  • Non-limiting examples of antidepressants include serotonin reuptake inhibitors (SSRIs), serotonin and dopamine reuptake inhibitors (SDRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin-noradrenaline-dopamine reuptake inhibitors (SNDRIs), noradrenergic and specific serotonergic anti-depressants (NASSAs), norepinephrine- dopamine reuptake inhibitors (NDRIs), norepinephrine (noradrenaline) reuptake inhibitors (NRIs), monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake enhancers (SSREs), melatonergic agonists, tryptamines, tricyclic antidepressants (TCAs), and atypical antidepressants.
  • SSRIs serotonin reuptake inhibitors
  • SDRIs
  • an SSRI, SDRI, SNRI, SNDRI, NASSA, NDRI, NRI, MAOI, SSRE, TCA or an atypical antidepressant is selected for, recommended to or administered to a subject who does not carry at least one thymidine allele at rsl 801 133, at least one guanine allele at rs 1805087, at least one thymine allele at rs800726 and at least one guanine at rs4680.
  • an SSRI such as fluoxetine, citalopram, paroxetine, escitalopram, sertraline, or a combination thereof is selected for the subject who does not carry these S Ps.
  • the subject is selected to receive one or more SSRIs, e.g., 1, 2, 3, 4, 5 or more SSRIs.
  • SSRIs act to prevent the reuptake of serotonin by the presynaptic neuron, thereby maintaining high levels of serotonin in the synapse.
  • SSRIs include, but are not limited to, the following (trade names in parentheses): alaproclate; amoxapine; citalopram (such as CELEXA ® , CIPRAMIL ® , EMOCAL ® , SEPRAM ® and SEROPRAM ® ); clomipramine; dapoxetine; duloxetine ⁇ e.g., CYMBALTA ® ); escitalopram oxalate ⁇ e.g., LEXAPRO ® , CIPRALEX ® and ESERTIA ® ); femoxetine; fenfluramine; fluoxetine ⁇ e.g.
  • PROZAC ® FONTEX ® , SEROMEX ® , SERONIL ® , SARAFEM ® , FLUCTIN ® (EUR), and FLUOX ® (NZ)); fluvoxamine maleate ⁇ e.g., LUVOX ® , FAVERIN ® , and DUMYROX ® ); indalpine; milnacipran; norfenfluramine; olanzapine; paroxetine ⁇ e.g., PAXIL ® , SEROXAT ® , AROPAX ® , DEROXAT ® , REXETIN ® , XETANOR ® , and PAROXAT ® ); sertraline ⁇ e.g., ZOLOFT ® , LUSTRAL ® and SERLAIN ® ); trazodone ⁇ e.g., DESYREL ® , MOLIPAXIN ® , TRITT
  • SSRIs and/or SRIs include, without limitations, citalopram, R-fluoxetine, nefazodone, imipramine, imipramine N-oxide, desipramine, pirandamine, dazepinil, nefopam, befuraline, fezolamine, cianoimipramine, litoxetine, cericlamine, seproxetine, WY 27587, WY 27866, imeldine, ifoxetine, tiflucarbine, viqualine, apelinaprine, YM 922, S 33005, F 98214TA, OPC 14523, cyanodothepine, trimipramine, quinupramine, dothiepin, , nitroxazepine, McN 5652, McN 5707, 01 77, Org 6582, Org 6997, Org 6906, amitriptyline, amitriptyline N-oxide, nortriptyline,
  • Bupropion e.g., WELLBUTRIN ®
  • SDRI serotonin and dopamine reuptake inhibitor
  • Non-limiting examples of SNRIs include: venlafaxine (EFFEXOR XR ® , EFFEXOR ® ); desvenlafaxine (PRISTIQ ® ); sibutramine (MERIDIA®, REDUCTIL ® ); nefazodone (SERZONE ® ); milnacipran (DALCIPRAN ® IXEL ® ); duloxetine (CYMBALTA ® ); and, bicifadine.
  • venlafaxine EFFEXOR XR ® , EFFEXOR ®
  • desvenlafaxine PRISTIQ ®
  • sibutramine MERIDIA®, REDUCTIL ®
  • nefazodone SELCIPRAN ® IXEL ®
  • duloxetine CYMBALTA ®
  • Non-limiting examples of SNDRIs include: tesofensine, brasofensine; NS2359; Nomifensine; Venlafaxine (EFFEXOR ® ) and Sibutramine (MERIDI A ® /REDUC TIL ® ) .
  • a non-limiting example of a NASSA includes mirtazapine (AVANZA®, ZISPIN ® , REMERON ® ).
  • NRIs include, without limitation, atomoxetine, maprotiline, nisoxetine, reboxetine, viloxazine and TCAs/Tetras (such as AMITRIPTYLINE®, AMOXAPINE ® , BUTRIPTYLINE ® ,
  • DESIPRAMINE ® /LOFEPRAMINE® DIBENZEPIN®, DOSULEPIN ® , DOXEPIN ® , IMIPRAMINE ® , IPRINDOLE ® , MELITRACEN ® , NORTRIPTYLINE ® , OPIPRAMOL ® , PROTRIPTYLINE ® , TRIMIPRAMINE ® , and MAPROTILINE ® ).
  • Non-limiting examples of MAOIs include: iproclozide, iproniazid, isocarboxazid, nialamide, pargyline, phenelzine, rasagiline, selegiline, toloxatone, tranylcypromine, REVIAs (brofaromine, beta-carbolines (harmaline) and moclobemide).
  • a non-limiting example of a SSRE includes tianeptine (STABLON ® , COAXIL ® , and TATINOL ® ).
  • a non-limiting example of a TCA includes desipramine (NORPRAMIN ® and PERTOFRANEIS ® ).
  • Additional antidepressants that can be used in the invention described herein can include, but are not limited to, natural products such as Kava-Kava, and St. John's Wort; dietary supplements such as s-adenosylmethionine; neuropeptides such as thyrotropin- releasing hormone; compounds targeting neuropeptide receptors such as neurokinin receptor antagonists; and hormones such as triiodothyronine.
  • the antidepressant drug dose can range from 0.1 mg/day to about 1000 mg/day, from about 0.5 mg/day to about 500 mg/day, from about 1 mg/day to about 400 mg/day, from about 5 mg/day to about 300 mg/day, or from about 10 mg/day to about 200 mg/day.
  • One of skill in the art can readily adjust dosage for each different antidepressant drug, depending on a number of factors such as types and/or potency of antidepressants, severity of depression, physical condition of a subject (e.g., ages, genders, and weights), administration routes, other medications taken by a subject, and any combinations thereof.
  • the therapeutically effective amount of the antidepressant drug monotherapy is sufficient to increase the degree of improvement in at least one neuropsychological test, e.g., as measured by HAMD-17, HAMD-28 or other efficacy measures, by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%), or at least about 90%, as compared to the degree of improvement obtained in the absence of the antidepressant drug.
  • the therapeutically effective amount of the antidepressant drug monotherapy is sufficient to increase the degree of improvement in at least one neuropsychological test, e.g., as measured by HAMD-17, HAMD-28 or other efficacy measures, by at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold or more, as compared to the degree of improvement obtained in the absence of the antidepressant drug.
  • any art-recognized folate drug e.g., folate-comprising compound
  • the folate drug comprises L-methylfolate.
  • the folate drug comprises 6(S)-5-methyltetrahydrofolate (also known as 6(S)-5-MTHF).
  • the folate drug can include at least one (including at least two, at least three or more) alkaline metal or alkaline earth metal salt of folate, e.g., but not limited to, a calcium salt of folate.
  • the folate drug is methyl folate, also known as Me-THF, N5-Methyl-THF, MTHF, 5-MTHF, L-methylfolate, and Levomefolic acid, or a pharmaceutically acceptable salt thereof (e.g., sodium salt, potassium salt, magnesium salt, calcium salt, glucosamine salt, or galactosamine salt).
  • Methyl folate calcium salt is available by prescription in the United States as DEPLIN ® (L-methylfolate calcium salt).
  • Methyl folate calcium salt is also available outside of the United States as METAFOLIN ® , BODYFOLIN ® , and NUTRIF OLIN ® .
  • the folate drug can include at least one (including at least two, at least three or more) glucosamine salt and/or galactosamine salt of folate (including, e.g., folic acid and reduced folate, e.g., but not limited to, tetrahydrofolate, and derivatives thereof).
  • glucosamine-folate and/or galactosamine-folate and derivatives thereof e.g., disclosed in U.S. Patent No. 7,947,662
  • QUATREFOLIC ® Gnosis S.p.A, Milan, IT
  • N-[4-[[[(6S)-2-amino-l,4,5,6,7,8-hexahydro-5-methyl-4-oxo-6- pteridinyl]methyl]amino]benzoyl]-L-glutamic acid, glucosamine salt can be administered to a human subject according to the methods described herein.
  • Additional examples of folates or folate-comprising compounds that can be administered to a subject according to the method provided herein include, but not limited to, the ones described in the U.S. Patent Nos. 4,336, 185; 6,921,754; and 7,947,662; and U.S. Pat. App. Publication No. US 2008/0064702, the disclosures of which are incorporated are herein incorporated by reference for all purposes.
  • the effective amount of folate for use in the treatment methods described herein can vary, depending upon the types of folate, severity of depression, physical conditions of a subject (e.g., ages, genders, weights).
  • the therapeutically effective amount of the folate containing compound monotherapy is sufficient to increase the degree of improvement in at least one neuropsychological test, e.g., as measured by HAMD-17, HAMD-28 or other efficacy measures, by at least about 5%, at least about 10%, at least about 20%), at least about 30%>, at least about 40%, at least about 50%, at least about 60%, at least about 70%), at least about 80%>, or at least about 90%, as compared to the degree of improvement obtained in the absence of the folate drug.
  • the therapeutically effective amount of the folate drug monotherapy is sufficient to increase the degree of improvement in at least one neuropsychological test, e.g., as measured by HAMD- 17, HAMD-28 or other efficacy measures, by at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold or more, as compared to the degree of improvement obtained in the absence of the folate drug.
  • the therapeutic drugs described herein e.g., antidepressant drugs
  • the methods of the present invention can be used to predict the therapeutic efficacy of an antidepressant drug in a subject having depression, e.g., major depressive disorder.
  • the methods of the present invention can also be used to predict the response of the subject to treatment with a drug monotherapy consisting of an antidepressant drug.
  • the methods of the invention can also be used to select a suitable antidepressant drug for the treatment of depression.
  • the drug monotherapy described herein can be administered alone or as part of a combined therapeutic approach with psychotherapy, psychodynamic therapy, cognitive behavior therapy and combinations thereof.
  • the drug monotherapy described herein can be administered via a single dosage form.
  • the single dosage form can be administered as a single tablet, pill, capsule for oral administration or a solution for parenteral administration.
  • the drug can be administered as separate compositions, e.g., as separate tablets or solutions.
  • the length of time between administrations of a sub-dose of a drug can be adjusted to achieve the desired therapeutic effect.
  • a dose of an antidepressant or a pharmaceutically acceptable salt thereof suitable for administration to a human is in the range of about 0.01 to 50 mg per kilogram body weight of the recipient per day, or in the range of 0.1 to 5 mg per kilogram body weight per day.
  • the desired dose can be presented as one single unit dosage form, e.g., containing about 1 mg to about 500 mg, or about 5 mg to about 300 mg.
  • the desired dose can be presented in two, three, four, five or more sub-doses administered at appropriate intervals throughout the day. These sub-doses can be administered in unit dosage forms, for example, containing about 0.1 mg to about 100 mg or about 1 mg to about 50 mg.
  • the therapeutically effective dose can be in the form of tablets, capsules, emulsions, suspensions, solutions, syrups, sprays, lozenges, powders, and sustained-release formulations.
  • Suitable excipients for oral administration include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, gelatin, sucrose, magnesium carbonate, and the like.
  • the pharmaceutically acceptable composition can be delivered via injection.
  • routes for administration include, but are not limited to, subcutaneous or parenteral including intravenous, intraarterial, intramuscular, intraperitoneal, intramyocardial, and infusion techniques.
  • the pharmaceutical acceptable composition is in a form that is suitable for injection.
  • the pharmaceutical composition is formulated for delivery by a catheter.
  • a pharmaceutical composition When administering a pharmaceutical composition parenterally, it can be generally formulated in a unit dosage injectable form (solution, suspension, emulsion).
  • the pharmaceutical formulations suitable for injection include sterile aqueous solutions or dispersions.
  • the carrier can be a solvent or dispersing medium containing, for example, water, cell culture medium, buffers (e.g., phosphate buffered saline), polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof.
  • the pharmaceutical carrier can be a buffered solution (e.g. PBS).
  • the pharmaceutical composition can be formulated in an emulsion or a gel.
  • the drug monotherapy e.g., antidepressant drug
  • slow-release or sustained release composition refers to continual delivery of a therapeutic agent in vivo over a period of time following administration.
  • sustained release can occur over a period of at least about 1 hour, at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 5 hours, at least about 6 hours, at least about 9 hours, at least about 12 hours, at least about 16 hours, at least about 24 hours following administration.
  • sustained release can occur over a period of at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days following administration.
  • the release of the drug monotherapy from a drug-delivery system can be steady state (zero-order kinetics) with at least about 30% ⁇ e.g., including at least about 40%, at least about 50%, at least about 60%>, at least about 70%, at least about 80%>, at least about 90%, at least about 95%) or more) of the drug compound released between about 3-6 hours post administration, or between about 4-5 hours post administration.
  • the release of the drug compound from a drug-delivery system can be steady state (zero-order kinetics) with substantially full release ⁇ e.g., -100%) of the drug released between about 3-6 hours post administration, or between about 4-5 hours post administration.
  • the drug compound can be released from a drug-delivery system at a rate that is slow enough not to overload the intestinal absorption capacity of a patient's duodenum.
  • a drug delivery system can comprise the drug compound encapsulated in polymer-based particles.
  • the folate-containing polymer-based particles can be filled into capsules or single-dose sachets for additional control of release.
  • Controlled-release ⁇ e.g., sustained release) drug delivery systems for different administration methods ⁇ e.g., oral administration, injection, implantation, and inhalation
  • different administration methods e.g., oral administration, injection, implantation, and inhalation
  • WO 2012/111961 oral formulation
  • WO 2012/131678 injectable formulation
  • US 2012/0258161 implantable formulation
  • US 2001/0038854 US 2001/0033866
  • a pharmaceutically acceptable carrier includes a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body.
  • a pharmaceutically-acceptable material, composition or vehicle such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body.
  • manufacturing aid e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid
  • solvent encapsulating material involved in
  • materials which can serve as pharmaceutically-acceptable carriers include: (i) sugars, such as lactose, glucose and sucrose; (ii) starches, such as corn starch and potato starch; (iii) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (iv) powdered tragacanth; (v) malt; (vi) gelatin; (vii) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (viii) excipients, such as cocoa butter and suppository waxes; (ix) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (x) glycols, such as propylene glycol; (xi) polyols, such as glycerin, sorbitol, mannitol and
  • compositions including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added.
  • antimicrobial preservatives for example, parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • isotonic agents for example, sugars, sodium chloride, and the like.
  • compositions can also contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, gelling or viscosity enhancing additives, preservatives, colors, binders, and the like, depending upon the route of administration and the preparation desired.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering agents, gelling or viscosity enhancing additives, preservatives, colors, binders, and the like, depending upon the route of administration and the preparation desired.
  • Standard texts such as "REMINGTON'S PHARMACEUTICAL SCIENCE”, 17th edition, 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation.
  • any vehicle, diluent, or additive used should have to be biocompatible with the antidepressant, the folate drug, or a pharmaceutically acceptable salt thereof.
  • compositions can be isotonic, i.e., they can have the same osmotic pressure as blood and lacrimal fluid.
  • the desired isotonicity of the compositions of the composition described herein can be accomplished using sodium chloride, or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol or other inorganic or organic solutes.
  • sodium chloride is used in buffers containing sodium ions.
  • Viscosity of the compositions can be maintained at the selected level using a pharmaceutically acceptable thickening agent.
  • methylcellulose is used because it is readily and economically available and is easy to work with.
  • suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like. The preferred concentration of the thickener will depend upon the agent selected. The important point is to use an amount which will achieve the selected viscosity. Viscous compositions are normally prepared from solutions by the addition of such thickening agents.
  • any additives in addition to the antidepressant and/or folate-comprising compound can be present in an amount of 0.001 to 50 wt % solution in phosphate buffered saline, and the active ingredient is present in the order of micrograms to milligrams to grams, such as about 0.0001 to about 5 wt %, about 0.0001 to about 1 wt %, about 0.0001 to about 0.05 wt % or about 0.001 to about 20 wt %, about 0.01 to about 10 wt %, and about 0.05 to about 5 wt %.
  • any therapeutic composition to be administered to a subject with compression and for any particular method of administration, it is preferred to determine toxicity, such as by determining the lethal dose (LD) and LD50 in a suitable animal model e.g., rodent such as mouse; and, the dosage of the composition(s), concentration of components therein and timing of administering the composition(s), which elicit a suitable response.
  • LD lethal dose
  • LD50 LD50
  • suitable animal model e.g., rodent such as mouse
  • compositions described herein can be prepared by mixing the ingredients following generally-accepted procedures.
  • the ingredients can be mixed in an appropriate pharmaceutically acceptable carrier and the mixture can be adjusted to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity.
  • the pH can vary from about 3 to about 7.5.
  • the pH of the composition can be about 6.5 to about 7.5.
  • Compositions can be administered in dosages and by techniques well known to those skilled in the medical and veterinary arts taking into consideration such factors as the age, sex, weight, and condition of the particular patient, and the composition form used for administration (e.g., liquid).
  • a subject can also be monitored at periodic time intervals to assess the efficacy of a certain therapeutic regimen. For example, the activation states of certain signal transduction molecules may change based on the therapeutic effect of treatment with one or more of the drugs described herein to treat depression. The subject can be monitored to assess response and understand the effects of certain drugs or treatments in an individualized approach. Additionally, subjects who initially respond to a specific drug for depression may become refractory to the drug, indicating that these subjects have developed acquired drug resistance. These subjects can be discontinued on their current therapy and an alternative treatment prescribed in accordance with the methods of the present invention.
  • a dose of the folate containing compound for administration to a human can be in the range of about 0.01 to about 50 mg per kilogram body weight of the recipient per day, in the range of about 0.05 to about 5 mg per kilogram body weight per day, or in the range of about 0.1 to about 1 mg per kilogram body weight per day.
  • the desired dose can be presented as one single unit dosage form, e.g., containing about 0.5 mg to about 500 mg, about 5 mg to about 250 mg, about 10 mg to about 100 mg, or about 10 mg to about 50 mg.
  • one single unit dosage form can provide about 1 mg to about 70 mg folate, about 5 mg to about 60 mg folate, or from about 7 mg to about 50 mg folate. In other embodiments, one single unit dosage form can provide about 15 mg to about 50 mg folate. In yet other embodiments, one single unit dosage form can provide about 20 mg folate.
  • the desired dose can be presented in two, three, four, five or more sub-doses administered at appropriate intervals throughout the day. These sub-doses can be administered in unit dosage forms, for example, containing about 0.1 mg to about 250 mg, about 1 mg to about 100 mg, about 2 mg to about 20 mg, or about 2 mg to about 10 mg.
  • the effective amount of folate administered to a selected human subject for the treatment of depression as described herein is significantly higher than the typical amount taken as a dietary supplement (between 50-600 ⁇ g/day).
  • the effective amount of folate administered to a selected human subject is at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 25-fold, at least about 50-fold, at least about 100-fold, at least about 250-fold, at least about 500-fold, at least about 1000-fold or more than the typical amount taken as a dietary supplement.
  • Example 1 Method for Selecting SSRI Monotherapy for Patients with Depression.
  • This example illustrates a method for selecting an effective treatment for a patient with depression.
  • This example also illustrates a method for identifying patients with depression, e.g., major depressive disorder (MDD), who are likely to respond to antidepressant drug monotherapy, e.g., SSRI monotherapy, and patients who will likely not respond to such therapy.
  • MDD major depressive disorder
  • This example shows that patients that do not carry the S Ps MTHFR 677 CT/TT (rsl8001133), MTR 2756 AG/GG (rsl805087), GCH1 TC/TT (rs8007267) and COMT Val58Met AG/GG (rs4680) positively responded to antidepressant drug monotherapy.
  • patients who responded to adjunctive therapy of an SSRI in combination with a folate-containing drug are positive for the MTHR and MTR SNPs and/or the GCH1 and COMT SNPs.
  • Patients were included in the study if they met the following criteria: 1) age 18-65 years and meeting the DSM-IV criteria for a current episode of MDD if they had a Quick Inventory of Depressive Symptoms-Self Report (QIDS-SR) score >12 at screening and baseline visits; 2) receiving an SSRI drug during the current episode of MDD for >8 weeks 66974688V.1 at adequate doses (defined as 20 mg/day or more of fluoxetine, citalopram, or paroxetine, 10 mg/day or more of escitalopram, and 50 mg/day or more of sertraline) as assessed using the Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire (ATRQ) (Chandler et al, CNS Neurosci Ther., 16:322-325 (2010)); and 3) maintaining a stable SSRI dose for the past 4 weeks.
  • QIDS-SR Quick Inventory of Depressive Symptoms-Self Report
  • SSRI-SSRI placebo-placebo
  • SSRI-L-methylfolate placebo-L-methylfolate 15 mg/day
  • L-methylfolate-L-methylfolate 15 mg/day during phases I and II using a randomization code generated by the primary study center.
  • Each phase was 30 days in duration.
  • Study visits occurred every 10 days during which the concomitant SSRI doses remained constant, and patients unable to tolerate the study medications were withdrawn from the study. Patients and investigators were blinded to study assignment.
  • Patients were assessed at each study visit with the Hamilton Depression Rating Scale (HDRS).
  • HDRS Hamilton Depression Rating Scale
  • symptom response was evaluated with the HAMD-28 (Mclntyre et al, J Psychiatry Neurosci, 27:235-239 (2002)), the Cognitive and Physical Function Questionnaire (CPFQ) (Fava et al, Psychother Psychosom, 78:91-97 (2009)), and the Clinical Global Impression Scale (CGI-S) (Guy W. Ecdeu. Assessment Manual for Psychopharmacology— Revised (DHEW Publ. No. ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs (1976)).
  • BMI was calculated in kg/m 2 .
  • Baseline blood samples were collected to assess baseline levels of plasma hsCRP, 4-hydroxy-2-nonenal (4-HNE), and low S-adenosylmethionine/S- adenosylhomocysteine (SAM/SAH) ratio.
  • C677T (677 CT/TT; rsl801133) genotype for methylenetetrahydrofolate reductase (MTHFR); b) the A2756G (2756 AG/GG; rs 1805087) genotype for methionine synthase (MTR); c) the TC/TT (rs8007267) genotype for GTP cyclohydrolase 1 (GCH1); and d) the Vall58Met AG/GG (rs4680) genotype for catechol-O-methyltransferase (COMT).
  • the pooled treatment effect was assessed by average differences in mean changes from baseline to endpoint for L-methylfolate and placebo groups, pooled across the two phases of the study, consistent with the SPCD of Fava et al, 2003.
  • the effect of biomarkers on the response on the HDRS-28 with L-methylfolate compared to placebo was stratified by BMI (>30 or ⁇ 30 kg/m 2 ), hsCRP level (median baseline value > or ⁇ 2.25 mg/L), SAM/SAH ratio (median baseline value > or ⁇ 2.71), and 4- HNE level (median baseline level > or ⁇ 3.28 ⁇ g/mL). Further, the presence of SNP genotypes was measured.
  • Elevated BMI, low ratio of SAM/SAH, elevated plasma levels of hsCRP, and 4-HNE, and molecular polymorphisms were evaluated as predictors of a greater pooled (phases I and II according to SPCD) drug/placebo difference.
  • a standard SPCD analysis approach was employed in order to analyze the study efficacy data. Specifically, an intent-to-treat/last observation carried forward (ITT/LOCF) approach was employed for patients treated with L-methylfolate during phase I.
  • the phase II dataset of interest was limited to patients treated with placebo during phase I and who completed phase I, who did not experience a clinical response on the HDRS during phase I and entered phase II.
  • the LOCF approach was applied to the dataset for phase II, with the final visit of phase I/first visit of phase II serving as the new baseline visit.
  • the data demonstrates that an SSRI monotherapy can be administered to a patient with depression who does not carry either of the SNP combinations.
  • the patients who did not carry the MTHFR, MTR, GCH1 and COMT SNPs had a greater mean change from baseline when administered an SSRI monotherapy (placebo in this study) than those patients who carried either the MTHFR and MTR SNP pairs or the GCH1 and COMT SNP pairs (- 8.3 ⁇ 6.9 vs. -3.8 ⁇ 6.4; Table 3).
  • the SNP marker negative patients exhibited a positive response to the SSRI drug.
  • the data indicates that a folate-containing drug can be administered to a patient who carries either SNP combination for the treatment of depression.
  • Further analysis revealed that patients who were positive for the MTHFR and MTR combination or the SNP combination of GCH1 TC/TT and COMT AG/GG showed a statistically significant clinical improvement if they received a folate drug (-1 1.1 ⁇ 9.8 vs -3.8 ⁇ 6.4, p ⁇ 0.001 ; Table 3).
  • Table 3 Effect of L-methylfolate Therapy in Patients with SNP Biomarker Pairs (MTHFR CT/TT and MTR AG/GG or GCHl TC/TT and COMT AG/GG) in Phase I of the Study
  • the data indicates that an SSRI drug can be administered as an effective treatment of depression in patients who do not carry the MTHFR CT/TT and MTR AG/GG SNP combination, the GCHl TC/TT and COMT GG SNP combination, or the GCHl TC/TT and COMT AG/GG SNP combination.
  • the SNPs MTHFR CT/TT, MTR AG/GG, GCH1 TC/TT and COMT AG/GG are useful for determining or predicting whether a depressed patient will respond to SSRI monotherapy or L-methylfolate adjunctive therapy.
  • L-methylfolate adjunctive therapy should be selected for a patient who is positive for one of the SNP pairs, e.g., (a) heterozygous or homozygous for the thymine "T" allele or complement thereof for the MTHFR SNP rsl801133, and heterozygous or homozygous for the guanine "G" allele or complement thereof for the MTR SNP rsl 805087; or (b) heterozygous or homozygous for the thymine "T” allele or complement thereof for the GCH1 SNP rs8007267, and heterozygous or homozygous for the guanine "G" allele or complement thereof for the COMT SNP rs4680.
  • SNP pairs e.g., (a) heterozygous or homozygous for the thymine "T" allele or complement thereof for the MTHFR SNP rsl801133, and heterozygous or homozygous for the guan
  • This patient is likely to respond to L- methylfolate adjunctive therapy, and not to respond to SSRI monotherapy.
  • this patient is predicted to have a good prognosis with L-methylfolate adjunctive therapy, but is predicted to have a bad or poor prognosis with SSRI monotherapy due to a lack of response to SSRI drugs.
  • a patient negative for both S P pairs should receive SSRI monotherapy. This patient is unlikely to respond to L-methylfolate adjunctive therapy and is predicted to have a positive response to SSRI monotherapy. Furthermore, a patient who is negative for the MTHFR, MTR, GCHl and COMT SNPs is likely to have a good prognosis if administered an SSRI monotherapy.
  • the SNP combinations described herein can be used to predict, determine, or select an effective therapy for patients with depression, including drug-naive patients (e.g., patients who have never been treated with SSRI drug therapy) and SSRI- resistant patients.

Abstract

L'invention concerne des méthodes servant à choisir un traitement par antidépresseur et/ou à prévoir une réaction positive à un traitement par antidépresseur, tel qu'un antidépresseur en monothérapie, chez un patient atteint de dépression, d'un trouble dépressif majeur par exemple. L'invention concerne également des méthodes permettant de déterminer un pronostic positif chez un patient déprimé recevant un médicament antidépresseur.
PCT/IB2015/051741 2014-03-11 2015-03-10 Méthodes de choix de traitement par antidépresseur pour traiter la dépression WO2015136446A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461951468P 2014-03-11 2014-03-11
US61/951,468 2014-03-11

Publications (1)

Publication Number Publication Date
WO2015136446A1 true WO2015136446A1 (fr) 2015-09-17

Family

ID=52737374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/051741 WO2015136446A1 (fr) 2014-03-11 2015-03-10 Méthodes de choix de traitement par antidépresseur pour traiter la dépression

Country Status (1)

Country Link
WO (1) WO2015136446A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182639A1 (fr) * 2017-03-30 2018-10-04 Rundle Research, LLC Méthodes de traitement de la dépression
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression
US11136386B2 (en) 2019-05-14 2021-10-05 Prometheus Biosciences, Inc. Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)
US20220202809A1 (en) * 2017-03-30 2022-06-30 Rundle Research Llc Methods of treating depression with vortioxetine

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336185A (en) 1976-03-02 1982-06-22 Rohm And Haas Company Folic acid derivatives
US20010033866A1 (en) 1998-10-01 2001-10-25 Jorg Ogorka Sustained release oral formulations
US20010038854A1 (en) 1996-06-26 2001-11-08 Yoshio Hata Sustained-release preparation
US6921754B2 (en) 2000-05-10 2005-07-26 Basf Aktiengesellschaft Compositions containing folic acid and reduced folate
US20080064702A1 (en) 2006-09-08 2008-03-13 Charalambos Antoniades Use of folates for the prevention and treatment of vascular diseases
US20080261220A1 (en) * 2000-11-30 2008-10-23 Third Wave Technologies, Inc. Nucleic Acid Detection Assays
US20090263879A1 (en) 2008-04-21 2009-10-22 Chiu Chin Chang Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples
US7947662B2 (en) 2008-02-20 2011-05-24 Gnosis S.P.A. Folates, compositions and uses thereof
WO2012111961A2 (fr) 2011-02-14 2012-08-23 지엘팜텍주식회사 Comprimé à libération prolongée, administré par voie orale, contenant de la tianeptine ou un sel pharmaceutiquement acceptable de celle-ci
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
WO2012131678A1 (fr) 2011-03-28 2012-10-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Formulation injectable à libération prolongée
US20120258161A1 (en) 2003-03-31 2012-10-11 Patel Rajesh A Implantable polymeric device for sustained release of dopamine agonist
WO2013074676A2 (fr) * 2011-11-14 2013-05-23 The General Hospital Corporation Dosages et procédés pour la sélection d'un schéma thérapeutique pour un sujet atteint d'une dépression

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336185A (en) 1976-03-02 1982-06-22 Rohm And Haas Company Folic acid derivatives
US20010038854A1 (en) 1996-06-26 2001-11-08 Yoshio Hata Sustained-release preparation
US20010033866A1 (en) 1998-10-01 2001-10-25 Jorg Ogorka Sustained release oral formulations
US6921754B2 (en) 2000-05-10 2005-07-26 Basf Aktiengesellschaft Compositions containing folic acid and reduced folate
US20080261220A1 (en) * 2000-11-30 2008-10-23 Third Wave Technologies, Inc. Nucleic Acid Detection Assays
US20120258161A1 (en) 2003-03-31 2012-10-11 Patel Rajesh A Implantable polymeric device for sustained release of dopamine agonist
US20080064702A1 (en) 2006-09-08 2008-03-13 Charalambos Antoniades Use of folates for the prevention and treatment of vascular diseases
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US7947662B2 (en) 2008-02-20 2011-05-24 Gnosis S.P.A. Folates, compositions and uses thereof
US20090263879A1 (en) 2008-04-21 2009-10-22 Chiu Chin Chang Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples
WO2012111961A2 (fr) 2011-02-14 2012-08-23 지엘팜텍주식회사 Comprimé à libération prolongée, administré par voie orale, contenant de la tianeptine ou un sel pharmaceutiquement acceptable de celle-ci
WO2012131678A1 (fr) 2011-03-28 2012-10-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Formulation injectable à libération prolongée
WO2013074676A2 (fr) * 2011-11-14 2013-05-23 The General Hospital Corporation Dosages et procédés pour la sélection d'un schéma thérapeutique pour un sujet atteint d'une dépression

Non-Patent Citations (47)

* Cited by examiner, † Cited by third party
Title
"American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders", WORLD HEALTH ORGANIZATION'S
"Analyzing DNA", vol. 1, 1997, COLD SPRING HARBOR LABORATORY PRESS, article "Genome Analysis: A Laboratory Manual"
"NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs", 1976, ROCKVILLE, MD, U.S. DEPARTMENT OF HEALTH, article "Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration"
"PCR Protocols, San Diego", 1990, ACADEMIC PRESS, INC.
"REMINGTON'S PHARMACEUTICAL SCIENCE", 1985
"The Polymerase Chain Reaction", 1994, BIRKHAUSER
AUSUBEL ET AL.: "Current Protocols in Genetics and Genomics", 1984, JOHN WILEY & SONS, INC.
AUSUBEL ET AL.: "Current Protocols in Human Genetics", 1984, JOHN WILEY & SONS, INC.
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", vol. 45, 1999, JOHN WILEY & SONS, INC.
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", vol. 47, 1984, JOHN WILEY & SONS, INC.
BREIMAN, MACHINE LEARNING, vol. 45, 2001, pages 5 - 32
BREIMAN: "Classification and Regression Trees", 1984, CHAPMAN AND HALL
CHANDLER ET AL., CNS NEUROSCI THER., vol. 16, 2010, pages 322 - 325
CHEE ET AL., SCIENCE, vol. 274, 1996, pages 610 - 614
CHEE NG ET AL: "Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8?weeks in major depression", HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, vol. 28, no. 5, 1 September 2013 (2013-09-01), pages 516 - 522, XP055196975, ISSN: 0885-6222, DOI: 10.1002/hup.2340 *
CRISTIANINI ET AL.: "An Introduction to Support Vector Machines and Other Kernel-Based Learning Methods", 2000, CAMBRIDGE UNIVERSITY PRESS
DE MATTIA E ET AL: "C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation", EUROPEAN JOURNAL OF CANCER, PERGAMON, vol. 45, no. 8, 1 May 2009 (2009-05-01), pages 1333 - 1351, XP026056385, ISSN: 0959-8049, [retrieved on 20090112], DOI: 10.1016/J.EJCA.2008.12.004 *
DELWART ET AL., SCIENCE, vol. 262, 1993, pages 1257 - 1261
DINAN TG., CURRENT OPINION PSYCHIA., vol. 22, no. 1, 2009, pages 32 - 6
DRMANAC ET AL., NATURE BIOTECH., vol. 16, 1998, pages 54 - 58
DRMANAC ET AL., SCIENCE, vol. 260, 1993, pages 1649 - 1652
FAVA ET AL., PSYCHOTHER PSYCHOSOM, vol. 72, 2003, pages 115 - 127
FAVA ET AL., PSYCHOTHER PSYCHOSOM, vol. 78, 2009, pages 91 - 97
FREEMAN ET AL.: "Neural Networks: Algorithms, Applications and Programming Techniques", 1991, ADDISON-WESLEY PUBLISHING COMPANY
FU ET AL., NATURE BIOTECH., vol. 16, 1998, pages 381 - 384
GEORGE I PAPAKOSTAS ET AL: "Article L-Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials", AM J PSYCHIATRY, vol. 169, 1 December 2012 (2012-12-01), pages 1267 - 1274, XP055196927 *
GERSHO ET AL.: "Vector Quantization and Signal Compression", 1992, KLUYWER ACADEMIC PUBLISHERS
HASHIDA ET AL., J CLIN. LAB. ANAL., vol. 11, 1997, pages 267 - 86
HASSOUN: "Fundamentals of Artificial Neural Networks", 1995, MIT PRESS
HAYASHI, METHODS APPLIC., vol. 1, 1991, pages 34 - 38
INNIS ET AL.: "PCR Protocols, San Diego", 1990, ACADEMIC PRESS, INC.
JARCHO ET AL.: "Dracopoli et al., Current Protocols in Human Genetics", JOHN WILEY & SONS, pages: 2.7.1 - 2.7.5
KUTYAVIN ET AL., NUC. ACIDS RESEARCH, vol. 28, 2000, pages 655 - 661
MANIATIS ET AL.: "Molecular Cloning: A Laboratory Manual", 1982, COLD SPRING HARBOR LAB.
MCINTYRE ET AL., J PSYCHIATRY NEUROSCI, vol. 27, 2002, pages 235 - 239
MISCHOULON DAVID ET AL: "Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment", CNS SPECTRUMS, MBL COMMUNICATIONS, NEW YORK, NY, US, vol. 17, no. 2, 1 June 2012 (2012-06-01), pages 76 - 86, XP009168179, ISSN: 1092-8529, DOI: 10.1017/S1092852912000430 *
PAPAKOSTAS ET AL., AM J PSYCHIATRY, vol. 169, 2012, pages 1267 - 1274
SEARS ET AL., BIOTECHNIQUES, vol. 13, 1992, pages 626 - 633
SHEFFIELD ET AL., IDENTIFYING DNA POLYMORPHISMS BY DENATURING GRADIENT GEL ELECTROPHORESIS, 1990
STEINBERG ET AL.: "CART: Tree-Structured Non-Parametric Data Analysis", SALFORD SYSTEMS, SAN DIEGO, 1995
TAMURA ET AL., CLIN TRIALS, vol. 4, 2007, pages 309 - 317
THEOPHILUS ET AL.: "PCR Mutation Detection Protocols", 2002, HUMANA PRESS
WHITE ET AL., GENOMICS, vol. 12, 1992, pages 301 - 306
WINTER ET AL., PROC. NATL. ACAD SCI., vol. 82, 1985, pages 7575 - 7579
ZADEH, IEEE TRANS. ON SYSTEMS, MAN AND CYBERNETICS, vol. 3, 1973, pages 28 - 44
ZADEH, INFORMATION AND CONTROL, vol. 8, 1965, pages 338 - 353
ZIMMERMAN ET AL., METHODS MOL. CELL BIOL., vol. 3, 1992, pages 39 - 42

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182639A1 (fr) * 2017-03-30 2018-10-04 Rundle Research, LLC Méthodes de traitement de la dépression
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression
AU2017407364B2 (en) * 2017-03-30 2019-11-07 Rundle Research, LLC Methods of treating depression
US10799498B2 (en) 2017-03-30 2020-10-13 Rundle Research, LLC. Methods of treating depression
US20220202809A1 (en) * 2017-03-30 2022-06-30 Rundle Research Llc Methods of treating depression with vortioxetine
US11136386B2 (en) 2019-05-14 2021-10-05 Prometheus Biosciences, Inc. Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)

Similar Documents

Publication Publication Date Title
US9546401B2 (en) Assays and methods for selecting a treatment regimen for a subject with depression
Claes et al. The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes
Eley et al. Association analysis of MAOA and COMT with neuroticism assessed by peers
KR20150131147A (ko) 우울증을 갖는 대상을 위해 치료 섭생법을 선별하기 위한 검정법 및 방법
US10072289B2 (en) Genetic addiction risk analysis for RDS severity index
US10857129B2 (en) V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
WO2006104812A2 (fr) Biomarqueurs pour le diagnostic pharmacogenetiques du diabete de type 2
WO2015136446A1 (fr) Méthodes de choix de traitement par antidépresseur pour traiter la dépression
Wigner et al. Variation of genes encoding KAT1, AADAT and IDO1 as a potential risk of depression development
JP2009518035A (ja) 疼痛感受性および慢性化に関する診断法およびテトラヒドロビオプテリン関連障害に関する診断法
US20060228750A1 (en) Method to determine the risk for side effects of an SSRI treatment in a person
US20090281090A1 (en) Biomarkers for the prediction of responsiveness to clozapine treatment
US20150265628A1 (en) Genomic testing for effective therapies and determination of dosing strategy
US20160058766A1 (en) Assays and methods for selecting a treatment regimen for a subject with depression
US20130029862A1 (en) Clinical application utilizing genetic data for effective medication management
Chen Pharmacogenetic Analysis of Antipsychotic Response in Schizophrenia
WO2014137705A1 (fr) Évaluation du risque d'encéphalopathie induite par le 5-fluorouracile ou la capécitabine
NZ624231B2 (en) Assays and methods for selecting a treatment regimen for a subject with depression

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15712194

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15712194

Country of ref document: EP

Kind code of ref document: A1